The compounds of the invention are potent and selective inhibitors of MIP-la binding to its receptor CCR1 found on inflammatory and immunomodulatory cells (preferably leukocytes and lymphocytes). The CCR1 receptor is also sometimes referred to as the CC- CKR1 receptor. These compounds also inhibit MlP-1a (and the related chemokine shown to <BR> <BR> <BR> <BR> interact with CCR1 (e 9, RANTES and MCP-3)) induced chemotaxis of THP-1 cells and human leukocytes and are potentially useful for the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult Respiratory Distress Syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection (chronic and acute), organ rejection (chronic and acute), atherosclerosis, restenosis, HIV infectivity (co- receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis).

MIP-la and RANTES are soluble chemotactic peptides (chemokines) which are produced by inflammatory cells, in particular CD8+ lymphocytes, polymorphonuclear leukocytes (PMNs) and macrophages, JBiol.Chem. EQ (30) 29671-29675 (1995). These chemokines act by inducing the migration and activation of key inflammatory and immunomodulatory cells. Elevated levels of chemokines have been found in the synovial fluid of rheumatoid arthritis patients, chronic and rejecting tissue transplant patients and in the nasal secretions of allergic rhinitis patients following allergen exposure (Teran , al., <BR> <BR> <BR> <BR> Immunol., 1806-1812 (1996), and Kuna ., al., J. Allergy Clin. Immunol. 321 (1994)).

Antibodies which interfere with the chemokine/receptor interaction by neutralizing MlP1a or gene disruption have provided direct evidence for the role of MIP-la and RANTES in disease by limiting the recruitment of monocytes and CD8+ lymphocytes (Smith Li!. 1 Immunol, 153, 4704 (1994) and Cook et et al., Science, 269,1583 (1995)). Together this data demonstrates that CCR1 antagonists would be an effective at treatment of severai immune based diseases. The compounds described within are potent and selective antagonists of CCR1. No other small molecule antagonists of the MlP-1a /RANTES interaction with CCR1 are currently known.

United States Patent 4,923,864, issued May 8, 1990, refers to certain heterocyclic hexanamides that are useful for treating hypertension.

PCT publication WO 89/01488, published February 23, 1989, refers to renin inhibiting peptides which possess nonpeptide linkages.

PCT publication WO 93/ 025057, published February 4, 1993, refers to dipeptide analogs which are claimed to inhibit retroviral proteases.

PCT publication WO 93/17003, published September 2, 1993, refers to other dipeptide analogs which are claimed to inhibit retroviral proteases.

PCT publication WO 92/17490, published October 15, 1992, refers to peptides containing at least one O-phosphate monoester or diester. The compounds are claimed to possess activity for inhibiting retroviruses.

European Patent Publication 708,085, published April 24, 1996, refers to antiviral ethers of aspartate protease inhibitors.

Summary of the Invention The present invention relates to compounds of the formula wherein R1 is (C2-Cg)heteroaryl optionally substituted with one or more substituents (preferably one to three substituents) independently selected from the group consisting of hydrogen, halo, CN, (C,-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C-C6)alkyl, (C,-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C,-C6)alkoxy(C,-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)-(C,-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(O=C)-, H(O=C)-(C,-C6)alkyl, (C1-C6)alkyl(O=C)-, (C,-C6)aikyl(O=C)-(C,-C6)alkyl, NO2, amino, (C,-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C,-C6)alkyl]2amino(C1-C6)alkyi, H2N-(C=O)-, (C1-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C,-C6)alkyl]2N-(C=O)-(C,-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C,-C6)alkyl(C=O)-

[NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C,-C6)alkyl, (C1-C6)alkyl-S-, (C,-C6)alkyl- (S=O)-, (C,-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C,-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C-C6)alkyl]2N-S02-(C,-C6)alkyl, OF3SO3-, (C,-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; R2 is phenyl-(CH2)m-, naphthyl-(CH2)m-, (C3-C10)cycloalkyl-(CH2)m-, (C1-C6)alkyl or (C2-C9)heteroaryl-(CH2)m-, wherein m is an interger from zero to four, wherein each of said phenyl, naphthyl, (C3-C10)cycloalkyl or (C2-Cg)heteroaryl moieties of said phenyl-(CH2)m-, naphthyl-(CH2)m-, (C3-C10)cycloalkyl-(CH2)m- or (C2-C9)heteroaryl-(CH2)m- groups may optionally be substituted with one or more substituents (preferably one to three substituents) independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C,-C6)alkyl, (C,-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)- (C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O- (C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)- (C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C,-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C,-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH)(01-06)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl (C1-C6)alkyl-S-, (C,-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2, H2N-SO2-(C1-C6)alkyl, (C,-C6)alkylHN-S02-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, OF3SO3-, (C1-C6)alkyl- SO,-, phenyl, phenoxy, benzyloxy, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-Cg)heteroaryl; R3 is hydrogen, (C1-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n-, (C2-C9)heterocycloalkyl- (CH2)n-, (C2-C9)heteroaryl-(CH2)n- or aryl-(CH2)n-; wherein n is an interger from zero to six; wherein said R3 (C1-C10)alkyl group may optionally be substituted with one or more substituents, (preferably from one to three substituents) independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)-(C1-C6)alkyl, NO2, amino, (C,-C6)alkylamino, [(01-06)alkyli2amino, amino(C1-C6)alkyl.

(C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C1-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C,-C6)alkyl-S-, (C,-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2 N-SO2-(C1-C6)alkyl, CF3SO3-, (C1-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)hetercycloalkyl, and (C2-Cg)heteroaryl; and wherein any of the carbon-carbon single bonds of said (C,-C,0)alkyl may optionally be replaced by a carbon-carbon double bond; wherein the (C3-C,O)cycloalkyl moiety of said R3 (C3-C10)cycloalkyl-(CH2)n- group may optionally be substituted by one to three substitutents independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C,-C6)alkyl, (C,-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C,-C6)alkoxy(C,-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)- (C,-C6)alkyl, (C,-C6)alkyl-O-(C=O)-(C,-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O- (C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)- (C,-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C1-C6)aikyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=0)-NH, (C1-C6)alkyl(C=0)- [NHJ(01-06)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S-, (C1-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkyl HN-S02-(C1-C6)alkyl, [(C,-C6)alkyl]2N-S02-(C,-C6)alkyl, OF3SO3-, (C1-C6)alkyl-SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; wherein the (C2-Cg)heterocycloalkyl moiety of said R3 (C2-Cg)heterocycloalkyl- (CH2)n- group may contain from one to three heteroatoms independently selected from nitrogen, sulfur, oxygen, >S(=O), >S02 or >NR6, wherein said (C2-C9)heterocycloalkyl moiety of said (C2-Cg)heterocycloalkyl-(CH2)n- group may optionally be substituted on any of the ring carbon atoms capable of forming an additional bond (preferably one to three substitutents per ring) with a substituent independently selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)-(C1-C6)alkyl,

(C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)-(C1-C6)alkyl, NO2, amino (C,-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(01-06)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C1-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C,-C6)alkyl-S-, (C,-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkylHN-S02-(C,-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, OF3SO3-, (C,-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; wherein the (C2-C9)heteroaryl moiety of said R3 (C2-C9)heteroaryl-(CH2)n- group may contain from one to three heteroatoms independently selected from nitrogen, sulfur or oxygen, wherein said (C2-Cg)heteroaryl moiety of said (C2-C9)heteroaryl-(CH2)n- group may optionally be substituted on any of the ring carbon atoms capable of forming an additional bond (preferably one to three substitutents per ring) with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C,-C6)alkyl, (C,-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)- (C,-C6)alkyl, (C,-C6)alkyl-O-(C=O)-(C,-C6)alkyl, (C,-C6)alkyl-(C=O)-O-, (C,-C6)alkyl-(C=O)-O- (C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)- (C1-C6)alkyi, NO2, amino (C1-C6)alkylamino, [(01-06)alkylbamino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C,-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S-, (C1-C6)alkyl- (S=O)-, (C,-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, CF3SO3-, (C1-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; and wherein said aryl moiety of said R3 aryl-(CH2)n- group is optionally substituted phenyl or naphthyl, wherein said phenyl and naphthyl may optionally be substituted with from one to three substituents independently selected from the group consisting of hydrogen halo, CN, (C,-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C,-C6)alkyl, (C,-C6)aikoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-

(C=O)-, (C,-C6)alkyl-O-(C=O)-, HO-(C=O)-(C,-C6)alkyl, (C,-C6)alkyl-O-(C=O)-(C,-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(O=C)-, (C1-C6)alkyl(O=C)-(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C1-C6)alkyl-NH-(C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)- (C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)-[NH](C1-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S-, (C,-C6)alkyl-(S=O)-, (C,-C6)alkyl- SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C,-C6)alkyl, (C,-C6)alkyl HN-SO2- (C,-C6)alkyl, [(C,-C6)alkyl]2N-S02-(C1-C6)alkyl, CF3S03-, (C1-C6)alkyl-S03-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; or R3 and the carbon to which it is attached form a five to seven membered carbocyclic ring, wherein any of the carbon atoms of said five membered carbocyclic ring may optionally be substituted with a substituent selected from the group consisting of hydrogen, halo, CN, (C,-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C,-C6)alkyl, (C,-C6)aikoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(O=C)-, H(0=C)-(C1-C6)alkyi, (C1-C6)alkyl(O=C)-, (C,-C6)alkyl(O=C)-(C1-C6)alkyl, NO2. amino, (C,-C6)alkylamino, [(C1-C6)alkyl]2amino, amino(C1-C6)alkyl, (C,-C6)alkylamino(C,-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C,-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C,-C6)alkyl-S-, (Cl-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C,-C6)alkylHN-S02-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, OF3SO3-, (C1-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-G9)heterocycloalkyl, and (C2-Cg)heteroaryl; wherein one of the carbon-carbon bonds of said five to seven membered carbocyclic ring may optionally be fused to an optionally substituted phenyl ring, wherein said substitutents may be independently selected from hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy-(C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)- (C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-

(C,-C6)alkyl, H(O=C)-, H(O=C)-(C1-C6)alkyl, (C1-C6)alkyl(0=C)-, (C,-C6)alkyl(0=C)- (C1-C6)alkyl, NO2, amino, (C,-C6)alkyiamino, [(C1-C6)alkyl]2amino, amino(C,-C6)alkyl, (C1-C6)alkylamino(C1-C6)alkyl, [(C1-C6)alkyl]2amino(C1-C6)alkyl, H2N-(C=O)-, (C1-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C,-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C,-C6)alkyl-S-, (C,-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2-, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, OF3SO3-, (C1-C6)alkyl- SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; R4 is hydrogen, (C1-C6)alkyl, hydroxy, (C1-C6)alkoxy, hydroxy(C1-C6)alkyl, (C1-C6)alkoxy(C=O)-, (C3-C10)cycloalkyl-(CH2)p-, (C2-C9)heterocycloalkyl-(CH2)p-, (C2-C9)heteroaryl-(CH2)p-, phenyl-(CH2)p-, or naphthyl-(OH2)-, wherein p is an integer from zero to four; wherein said (C2-C9)heterocycloalkyl, (C2-Cg)heteroaryl, phenyl and naphthyl groups of said (C2-C9)heterocycloalkyl-(CH2)p-, (C2-C9)heteroaryl-(CH2)p-, phenyl-(CH2)p-, or naphthyl-(OH2)- may be optionally substituted on any of the ring atoms capable of supporting an additional bond (preferably zero to two substituents per ring) with a substituent selected from the group consisting of hydrogen, halo, CN, (C1-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy, hydroxy- (C1-C6)alkyl, (C1-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C1-C6)alkoxy(C1-C6)alkyl, HO-(C=O)-, (C1-C6)alkyl-O-(C=O)-, HO-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl,(C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl- (C=0)-0-(C,-C6)alkyl, H(O=C)-, H(0=C)-(C,-C6)alkyl, (C,-C6) alkyl(0=C)-, (C,-C6)alkyl(0=C)- (C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyi]2 amino, amino(C1-C6)alkyl, (C,-C6)alkylamino (C,-C6)alkyl, [(C1-C6)alkyl]2amino(C,-C6)alkyl, H2N-(C=O)-, (C,-C6)alkyl-NH- (C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)-(C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)- [NH](C1-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (C1-C6)alkyl-S-, (C1-C6)alkyl- (S=O)-, (C1-C6)alkyl-SO2, (C1-C6)alkyl-SO2-NH-, H2N-SO2-, H2N-SO2-(C1-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, CF3SO3-, (C1-C6)alkyl-SO3, phenyl, (C3-C,0)cycloalkyi, (C2-C9)heterocycloalkyl, and (C2-Cg)heteroaryl; or R4 and R5 together with the nitrogen atom to which they are attached form a (C2- Cg)heterocycloalkyl group wherein any of the ring atoms of said (C2-C9)heterocycloalkyl group may optionally be substituted, preferably from zero to two substituents, with a substituent selected from the group consisting of hydrogen, halo CN, (C,-C6)alkyl optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), hydroxy,

hydroxy-(C1-C6)alkyl, (C,-C6)alkoxy optionally substituted with one or more fluorine atoms (preferably one to three fluorine atoms), (C,-C6)alkoxy(C,-C6)alkyl, HO-(C=O)-, (C,-C6)alkyl-0- (C=O)-, HO-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H(0=C)-, H(0=C)-(C1-C6)alkyl, (C1-C6) alkyl(0=C)-, (C1-C6)alkyl(0=C)-(C1-C6)alkyl, NO2, amino, (C1-C6)alkylamino, [(C1-C6)alkyl]2 amino, amino(C1-C6)alkyi, (C1-C6)alkylamino (C,-C6)alkyl, [(C,-C6)alkyl]2amino(C,-C6)alkyl, H2N- (C=O)-, (C1-C6)alkyl-NH-(C=O)-, [(C1-C6)alkyl]2N-(C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl- HN(C=O)-(C1-C6)alkyl, I(C,-C,)alkyl],N-(C=O)-(C,-C,)alkyl, H(0=C)-NH-, (C,-C6)alkyl(C=0)- NH, (C1-C6)alkyl(C=O)-[NH](C1-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, (Cl-C6)alkyl-S-, (Cl-C6)alkyl-(S=O)-, (Cl-C6)alkyl-SO2-, (Cl-C6)alkyl-SO2-NH-, H2N-SO2-, H2N- SO2-(C1-C6)alkyl, (C1-C6)alkylHN-SO2-(C1-C6)alkyl, [(C1-C6)alkyl]2N-SO2-(C1-C6)alkyl, CF3SO3-, (C1-C6)alkyl-SO3-, phenyl, (C3-C10)cycloalkyl, (C2-C9)heterocycloalkyl, and (C2-C9)heteroaryl; R5 is hydrogen, (C,-C6)alkyl or amino; R6 is hydrogen, (C1-C6)alkyl, (C1-C6)alkoxy-(CH2)g-, (C1-C6)alkoxy(C=O)-(CH2)g-, (C1-C6)alkyl-(SO2)-(CH2)g-, (C6-C10)aryloxy-(CH2)g-, (C6-C10)aryloxy(C=O)-(CH2)g-, or (C6-C10)aryl-(S02)-(CH2)9-, wherein g is an integer from zero to four; with the proviso that when one of R4 or R5 is hydrogen, and the other of R4 or R5 is (C1-C6)alkyl; R2 is (C3-C,O)cycloalkyl or isopropyl and R3 is (C3-Cs)alkyl, phenyl, methylvinyl, dimethylvinyl, halovinyl, hydroxy(C1-C3)alkyl or amino(C,-C4)alkyl then R' must be other than indol-5-yl, 6-azaindol-2-yl, 2,3-dichloro-pyrrol-5-yl, 4-hydroxyquinolin-3-yl, 2- hydroxyquinoxalin-3-yl, 6-azaindolin-3-yl, or optionally substituted indol-2 or 3-yl; and the pharmaceutically acceptable salts of such compounds.

The present invention also relates to the pharmaceutically acceptable acid addition salts of compounds of the formula I. The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the aforementioned base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as the hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate, bisulfate, phosphate, acid phosphate, acetate, lactate, citrate, acid citrate, tartrate, bitartrate. succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate, ethanesulfonate, benzenesulfonate, p-toluenesulfonate and pamoate [i.e., 1,1 '-methylene-bis-(2-hydroxy-3- naphthoate)]salts.

The invention also relates to base addition salts of formula I. The chemical bases that may be used as reagents to prepare pharmaceutically acceptable base salts of those compounds of formula I that are acidic in nature are those that form non-toxic base salts with such compounds. Such non-toxic base salts include, but are not limited to those derived from

such pharmacologically acceptable cations such as alkali metal cations (, potassium and sodium) and alkaline earth metal cations (e.a., calcium and magnesium), ammonium or water- soluble amine addition salts such as N-methylglucamine-(meglumine), and the lower alkanolammonium and other base salts of pharmaceutically acceptable organic amines.

The compounds of this invention may contain olefin-like double bonds. When such bonds are present, the compounds of the invention exist as cis and trans configurations and as mixtures thereof.

Unless otherwise indicated, the alkyl and alkenyl groups referred to herein, as well as the alkyl moieties of other groups referred to herein (erg, alkoxy), may be linear or branched, and they may also be cyclic (e.g., cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl or cycloheptyl) or be linear or branched and contain cyclic moieties. Branched groups such as 2- methylbutyl, 2-methylpentyl are defined such that the lowest number is the carbon furthest from the point of attachment. Unless otherwise indicated, haiogen includes fluorine, chlorine, bromine, and iodine.

(C3-C10)Cycloalkyl when used herein refers to cycloalkyl groups containing zero to two levels of unsaturation such as cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, 1,3cyclohexadiene, cycloheptyl, cycloheptenyl, bicyclo[3.2. 1 joctane, norbornanyl etc..

(C2-Cg)Heterocycloalkyl when used herein refers to pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydropyranyl, pyranyl, thiopyranyl, aziridinyl, oxiranyl, methylenedioxyl, chromenyl, isoxazolidinyl, 1,3-oxazolidin-3-yl, isothiazolidinyl, 1,3-thiazolidin-3-yl, 1,2- pyrazolidin-2-yl, 1 ,3-pyrazolidin-1-yl, piperidinyl, thiomorpholinyl, 1 ,2-tetrahydrothiazin-2-yl, 1,3- tetrahydrothiazin-3-yl, tetrahydrothiadiazinyl, morpholinyl, 1,2-tetrahydrodiazin-2-yl, 1,3- tetrahydrodiazin-1-yl, tetrahydroazepinyl, piperazinyl, chromanyl, etc. One of ordinary skill in the art will understand that the connection of said (C2-Cg)heterocycloalkyi rings is through a carbon or a sp3 hybridized nitrogen heteroatom.

(C2-Cg)Heteroaryl when used herein refers to furyl, thienyl, thiazolyl, pyrazolyl, isothiazolyl, oxazolyl, isoxazolyl, pyrrolyl, triazolyl, tetrazolyl, imidazolyl, 1,3, 5oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,3-oxadiazolyl, 1,3,5-thiadiazolyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, pyridyl, pyrimidyl, pyrazinyl, pyridazinyl, 1,2,4-triazinyl, 1,2,3-triazinyl, 1,3,5-triazinyl, pyrazolo[3,4-b]pyridinyl, cinnolinyl, pteridinyl, purinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzo[b]thiophenyl, 5, 6, 7, 8-tetrahydroquinolin-3-yl, benzoxazolyl, benzothiazoiyl. benzisothiazolyl, benzisoxazolyl, benzimidazolyl, thianaphthenyl, isothianaphthenyl, benzofuranyl, isobenzofuranyl, isoindolyl, indolyl, indolizinyl, indazolyl, isoquinolyl, quinolyl, phthalazinyl, quinoxalinyl, quinazolinyl, benzoxazinyl; etc. One of ordinary skill in the art will

understand that the connection of said (C2-Cg)heterocycloalkyl nngs is through a carbon atom or a sp3 hybridized nitrogen heteroatom.

Aryl when used herein refers to phenyl or naphthyl.

The compounds of this invention include all conformational isomers (, cis and trans isomers) and all optical isomers of compounds of the formula I (e.g., enantiomers and diastereomers), as well as racemic, diastereomeric and other mixtures of such isomers.

Preferred compounds of the of formula I include those with the stereochemistry depicted in formula Preferred compounds of the formula I include those wherein R' is optionally substituted pyrazolo[3,4-b]pyridinyl, cinnolinyl, pyridinyl, 6,7-dihydro-5H-[1]pyrindinyl, benzothiazolyl, indolyl, pyrazinyl, benzoimidazolyl, benzofuranyl, benzo[b]thiophenyl, naphthalenyl, quinoxalinyl, isoquinolinyl, 5,6,7,8-tetrahydro-quinolin-3-yl or quinolinyl, more preferably pyrazolo[3,4-b]pyridin-5-yl, cinnolin-4-yl, pyridin-2-yl, 6,7-dihydro-5H-[1]pyrindin-3-yl, benzothiazol-2-yl, indol-2-yl, pyrazin-2-yl, benzoimidazol-2-yl, benzofuran-2-yl, benzo[b]thiophen-2-yl, naphthalen-2-yl, quinoxalin-2-yl, quinoxalin-6-yl, isoquinolin-1 -yl, isoquinolin-3-yl, isoquinolin4-yl, 5,6,7,8-tetrahydro-quinolin-3-yl, quinolin-2-yl, quinolin-3-yl, quinolin4-yl or quinolin4-yl, most preferably quinoxalin6-yl, quinolin-2-yl, quinolin-3-yl, quinoxalin-2-yl, quinolin4-yl or quinolin6-yl.

Other preferred compounds of formula I include those wherein R2 is optionally substituted phenyl, benzyl, naphthyl, cyclohexyl, thienyl, thiazolyl, pyridyl, oxazolyl, furanyl, or thiophenyl; wherein said substituents are independently selected from hydrogen, halo, (C1-C6)alkyl, trifluoromethyl, trifluoromethoxy, hydroxy, -C(=O)-OH, (C1-C6)alkoxy, (C1-C6)alkoxy(C=O)-, NO2, amino, (C,-C6)alkylamino, [(C1-C6)alkyl]2amino, (C1-C6)alkyl-O- (C=O)-, HO-(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-O-(C=O)-(C1-C6)alkyl, (C,-C6)alkyl-(C=O)-O-, (C1-C6)alkyl-(C=O)-O-(C1-C6)alkyl, H2N-(C=O)-, (C,-C6)alkyl-NH-(C=O)-, [(C,-C6)alkyl]2N- (C=O)-, H2N(C=O)-(C1-C6)alkyl, (C1-C6)alkyl-HN(C=O)-(C1-C6)alkyl, [(C1-C6)alkyl]2N-(C=O)- (C1-C6)alkyl, H(O=C)-NH-, (C1-C6)alkyl(C=O)-NH, (C1-C6)alkyl(C=O)-[NH](C1-C6)alkyl, (C1-C6)alkyl(C=O)-[N(C1-C6)alkyl](C1-C6)alkyl, phenoxy, and benzyloxy.

Other preferred compounds of formula I include those wherein R3 is optionally substituted (C,-C,O)alkyl, benzyl, pyranyl or (C3-C,O)cycloalkyl-(CH2)n-, wherein any of the carbon-carbon single bonds of said (C1-C10)alkyl may be optionally replaced by a carbon- carbon double bond; more preferably optionally substituted n-butyl, t-butyl, 2-methylpropyl, 2-methylbutyl, 3-methylbutyl, n-pentyl, 2-methyl-pentyl, allyl, cyclopentyl, cyclohexyl 2- methylcyclohexyl, cyclohexylmethyl, or cycloheptyl, more preferably wherein the substituent is fluoro, (C,-C6)alkyl or hydroxy.

Examples of specific preferred compounds of the formula I are the following: 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)-amide; 8-fluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1 (S)-(3-fluoro-benzyl)-2(S)- hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1 (S)-(2-fluoro-benzyl)-2(S)-hydroxy- 7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-4-(2,6-dimethyl- tetrahydro-pyran4-yi)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-5-cyclohexyl-2(S)-hydroxyA(R)- methylcarbamoyl-pentyl)]-amide; quinoxaline-2-carboxylic acid [1 (S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxy4(S)-hydroxycarbamoyl-4- (1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-(4,4-difluoro-1 -hydroxy-cyclohexyl)- 2(S)-(hydroxy4.hydroxycarbamoyl-butyl)]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-4(S)-(4,4-difluoro- cyclohexyl)-2(S)-hydroxy-butyl]-amide; quinoline-3-carboxylic acid (1(S)-benzyl4(S)-carbamoyl4-cyclohexyl-2(S)-hydroxy- butyl)-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1 (S)-thiophen- 2-ylmethyl-octyl)-amide;

quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy- oct-6-enyl)]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl- pentyl)]-amide; N-(1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl -octyl)-5,6-dichloro- nicotinamide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S).hydroxy-7-methyl- 1 (5)-thiazolA- ylmethyl-octyl)-amide; benzothiazole-2-carboxylic acid [1 (S)-benzyl-4( R)-carbamoyl-7-fluoro-2( S)-hydroxy- 7-methyl-octyl)j-amide; and benzofuran-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)]-amide.

Examples of other compounds of the formula I are the following: quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1 -thiazolA- ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid (7-fluoro-2-hydroxy4-hydroxycarbamoyl-7-methyl-1- thiazol4-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl- cyclohexyl)-1-thiazol4-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)- 1 -thiazol-4-ylmethyJ-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl4-(4,4-difluoro-cyclohexyl)-2-hyd roxy- 1 - thiazol9-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4- hydroxycarbamoyl-1 -thiazol-4-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-1 -(3,5-difluoro-benzyl)-7-fluoro-2- hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-7-fluoro-2-hydroxy4- hydroxycarbamoyl-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3,5-difluoro-benzyl)-2-hydroxy4-(1- hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)-2-hydroxy-4- hyd roxycarbamoyl4-(1 -hyd roxy4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3,5-difluoro-benzyl)-4-(4,4-difluoro- cyclohexyl)-2-hydroxy-butyl]-amide;

quinoxaline-2-carboxylic acid [1-(3,5-difluoro-benzyl)4-(4,4-difluoro-cycloheXyl)-2- hydroxy4-hydroxycarbamoyl-butyl]-amide; quinoxaline-2-carboxylic acid (4-carbamoyl-2-hydroxy-7-methyl-l -pyridin-2-ylmethyl- octyl)-amide; quinoxaline-2-carboxylic acid (7-fluoro-2-hydroxy-4-hyd roxycarbamoyl-7-methyl- 1 - pyridin-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid [4-carbamoyl4-(2,6-dimethyl-tetrahydro-pyran4-yl)-2- hydroxy-1 -pyridin-2-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)-1 -pyridin-2-ylmethyl-butylj-amide; quinoxaline-2-carboxylic acid (4-carbamoyl-4-cyclohexyl-2-hydroxy-1-pyridin-2- ylmethyl-butyl)-amide; quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4- hydroxycarbamoyl-1 -pyridin-2-yimethyl-butyl]-amide; quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1 -pyrid in-3- ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid (2-hydroxy-4-hydroxycarbamoyl-7-methyl-l -pyridin-3- ylmethyloctyl)-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl- cyclohexyl)-1 -pyridin-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-(2,6-dimethyl-tetrahydro-pyran4-yl)-2-hydroxy4- hydroxycarbamoyl-1 -pyridin-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy- 1 - pyridin-3-ylmethyl-butyl]-amide; quinoxaline-2carboxylic acid (4-cyclohexyl-2-hydroxy4-hydroxycarbamoyl-1- pyridin-3-ylmethyi-butyl)-amide; quinoxaline-2-carboxylic acid [4-carbamoyi-7-fluoro-1-(4-fluoro-benzyl)-2-hydroxy-7- methyl-octyl]-amide; quinoxaline-2-carboxylic acid [7-fluoro-1-(4-fluoro-benzyl)-2-hydroxy-4- hydroxycarbamoyl-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4carbamoyl-l -(4-fluoro-benzyl)-2-hydroxy-4-( 1- hydroxy4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1 -(4-fluoro-benzyl)-2-hydroxy4-hydroxycarbamoyl4- (1 -hydroxy4-methyl-cyclohexyl)-butyl]-amide;

quinoxaline-2carboxylic acid [4-carbamoyl4-(4,4-difluoro-cyclohexyl)-1-(4-fluoro- benzyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-1-(4-fluoro-benzyl)-2- hydroxy-4-hydroxycarbamoyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-1-(3-fluoro-benzyl)-2-hydroxy-4-(1- hydroxy-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [7-fluoro-1-(3-fluoro-benzyl)-2-hydroxy-4- hydroxycarbamoyl-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-4-(2,6-dimethyl-tetrahydro-pyran-4-yl)-1 - (3-fluoro-benzyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [1 -(3-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4- (1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-1-(3-fluoro- benzyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [4-cyclohexyl-1-(3-fluoro-benzyl)-2-hydroxy-4- hydroxycarbamoyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-1-(2-fluoro-benzyl)-2-hydroxy-4-(1- hydroxy-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [7-fluoro-1 -(2-fluoro-benzyl)-2-hydroxy4- hydroxycarbamoyl-7-methyl-octy l]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl4-(2,6-dimethyl-tetrahydro-pyran4-yl)-1- (2-fluoro-benzyl)-2-hydroxy-butyl]-amide; qu inoxaline-2-carboxylic acid [1 -(2-fluoro-benzyl)-2-hydroxy-4-hydroxycarbamoyl-4- (1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2carboxylic acid [4-carbamoyl4-(4,4-difluoro-cyclohexyl)-1-(2-fluoro- benzyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [4-cyclohexyl-1-(2-fluoro-benzyl)-2-hydroxy-4- hydroxycarbamoyl-butyl]-amide; quinoxaline-2-carboxylic acid (4-carbamoyl-7-fluoro-2-hydroxy-7-methyl-1-thiophen- 2-ylmethyl-octyl)-amide; quinoxaline-2carboxylic acid (7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1 - thiophen-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-4-(1-hydroxy-4-methyl- cyclohexyl)-1 -thiophen-2-ylmethyl-butyl]-amide;

quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)-1-thiophen-2-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1- thiophen-2-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-(4,4-difluoro-cyclohexyl)-2-hydroxy-4- hydroxycarbamoyl-1 -thiophen-2-ylmethyl-butyl]-amide; quinoxaline-2<:arboxylic acid [4-carbamoyl-2-hydroxy-7-methyl-1 -(3-trifluoromethy 1- benzyl)-octyl]-amide; q uinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy4-hydroxycarbamoyl-7-methyl-1 - (3-trifluoromethyl-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(4-hydroxy-2,6-dimethyl- tetrahydro-pyran4-yl)-1 -(3-trifluoromethyl-benzyl)-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)- 1 -(3-trifluoromethyl-benzyl)-butyl]-amide; quinoxaline-2-carboxylic acid {4-carbamoyl-4-cyclohexyl)-2-hydroxy-1-(3- trifluoromethyl-benzyl)-butyl)-amide; q uinoxaline-2-carboxylic acid {4-hydroxycarbamoyl4-(4,4-difluoro-cyclohexyl)-2- hydroxy-1-(3-trifluoromethyl-benzyl)-butyl}-amide; qu inoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1 -(3- trifluoromethoxy-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-2-hydroxy-7-methyl-1-(3- trifluoromethoxy-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl- cyclohexyl)-1-(3-trifluoromethoxy-benzyl)-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(4-hydroxy-2,6- dimethyl-tetrahydro-pyran-4-yl)-1-(3-trifluoromethoxy-benzyl )-butyl]-amide; quinoxaline-2carboxylic acid {4-carbamoyl4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1- (3-trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-cyclohexyl)-2-hydroxy-1-(3- trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-(4- trifluoromethoxy-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-hydroxycarbamoyl-7-methyl-1- (4-trifluoromethoxy-benzyl)-octyl]-amide;

quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl- cyclohexyl)-1-(4-trifluoromethoxy-benzyl)-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)-1-(4-trifluoromethoxy-benzyl)-butyl]-amid e; quinoxaline-2-carboxylic acid {4-carbamoyl-4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1- (4-trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl4-(4,4-difluoro-cyclohexyl)-2- hydroxy-1-(4-trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid [4-carbamoyl-2-hydroxy-7-methyl-1-(2-trifluoromethyl- benzyl)-octylj-amide; quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy4-hydroxycarbamoyl-7-methyl-1- (2-trifluoromethoxy-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyi4-(4-hydroxy-2,6-dimethyl- tetrahydro-pyran-4-yl)-1-(2-trifluoromethoxy-benzyl)-butyl]- amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)-1-(2-trifluoromethoxy-benzyl)-butyl]-amid e; quinoxaline-2-carboxylic acid {4-carbamoyl-4-cyclohexyl)-2-hydroxy-1-(2- trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl4-(4,4-difluoro-cyclohexyl)-2- hydroxy-1-(2-trifluoromethoxy-benzyl)-butyl}-amide; quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-[3-(1- hyd roxy-1 -methyl-ethyl)-benzyl]-octyl]-amide; quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-2-hydroxy-7-methyl -1 -[3-( 1 - hydroxy-1 -methyl-ethyl)-benzyl]-octyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl- cyclohexyl).1 -[3-(1 -hydroxy-1 -methyl-ethyl)-benzyl]-butyl}-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(4-hydroxy-2,6- dimethyl-tetrahydro-pyran4-yl)-1 -3-( 1 -hydroxy-1 -methyl-ethyl)-benzyl)-butyl]-amide; quinoxaline-2-carboxylic acid (4-carbamoyl4-(4 ,4-d ifluoro-cyclohexyl)-2-hydroxy- 1 - [3-(1 -hydroxy-1 -methyl-ethyl)-benzyl]-butyl}-amide; quinoxaline-2-carboxylic acid {4-hydroxycarbamoyl-4-(cyclohexyl)-2-hydroxy-1-[3-(1- hydroxy-1 -methyl-ethyl)-benzyI]-butyl)-amide; quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy-4-carbamoyl-7-methyl-1-thiophen- 3-ylmethyl-butyl]-amide;

quinoxaline-2-carboxylic acid [7-fluoro-2-hydroxy4-hydroxycarbamoyl-7-methyl-1- thiophen-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-carbamoyl-4-(1-hydroxy-4-methyl- cyclohexyl)-1 -thiophen-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [2-hydroxy-4-hydroxycarbamoyl-4-(1-hydroxy-4- methyl-cyclohexyl)-1 -thiophen-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-carbamoyl4-(4,4-difluoro-cyclohexyl)-2-hydroxy-1- thiophen-3-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [4-hydroxycarbamoyl-4-(4,4-difluoro-cyclohexyl)-2- hyd roxy- 1 -thiophen-3-ylmethyl-butyl]-amide; [[1 ,8]naphthyridine-3-carboxylic acid (1 -benzyl4-carbamoy l-7-fluoro-2-hydroxy-7- methyl-octyl)-amide; [1, 8]naphthyridine-3-carboxylic acid (1 -benzyl-7-fluoro-2-hydroxy4- hydroxycarbamoyl-7-methyl-octyl)-amide; [1, 8]naphthyridine-3-carboxylic acid [1 -benzyl-4-carbamoyl-2-hydroxy-4-(1-hydroxy- 4-methyl-cyclohexyl)-butyl]-amide; [1,8]naphthyridine-3-carboxylic acid [1 -benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1- hydroxy-4-methyl-cyclohexyl)-butyl]-amide; [1,5]naphthyridine-3-carboxylic acid (1-benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7- methyl-octyl)-amide; [1,5]naphthyridine-3-carboxylic acid (1 -benzyl-7-fluoro-2-hydroxy-4- hydroxycarbamoyl-7-methyl-octyl)-amide; [1,5]naphthyridine-3-carboxylic acid [1 -benzyi4-carbamoyl-2-hydroxy4-(1 -hydroxy- 4-methyl-cyclohexyl)-butyl]-amide; [1,5]naphthyridine-3-carboxylic acid [1 -benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1- hydroxy-4-methyl-cyclohexyl)-butyl]-amide; 1, 8]naphthyrid ine-2-carboxylic acid (1 -benzyl-4-carbamoyl-7-fluoro-2-hydroxy-7- methyl-octyl)-amide; [1,8]naphthyridine-2-carboxylic acid (1 -benzyi-7-fluoro-2-hydroxy4- hydroxycarbamoyl-7-methyl-octyl)-amide; [1 ,8]naphthyridine-2-carboxylic acid [1 -benzyl4-carbamoyl-2-hydroxy4-(1 -hydroxy- 4-methyl-cyclohexyl)-butyl]-amide; [1,8]naphthy ridine-2-carboxylic acid [1-benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1 - hydroxy-4-methyl-cyclohexyl)-butyl]-amide;

[1 ,6]naphthyridine-2-carboxylic acid (1 -benzyl4-carbamoyl-7-fluoro-2-hydroxy-7- methyl-octyl)-amide; [1 ,6]naphthyridine-2-carboxylic acid(l -benzyl-7-fluoro-2-hydroxy4- hydroxycarbamoyl-7-methyl-octyl)-amide; [1 ,6]naphthyridine-2-carboxylic acid [1 -benzyl4-carbamoy 1-2-hydroxy-4-(1 1 -hydroxy- 4-methyl-cyclohexyl)-butyl]-amide; [1 ,6]naphthyridine-2-carboxylic acid [1 -benzyl-2-hydroxy-4-hydroxycarbamoyl-4-(1 - hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; q uinoxaline-2-carboxylic acid (6-chloro-1 (S)-cyclohexylmethyl-2(S)-hydroxy-4(S)- methylcarbamoyl-hept-6-enyl)-amide; quinoline-3-carboxylic acid (2(S)-hydroxy-1(S)-isobutyl-6-methyl4(R) methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1(S)-sec-butyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-hept-6-enyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-hept-6-enyl)-amide; N-1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)-methylcar bamoyl-heptyl)-5- phenyl-nicotinamide; quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-cyclohexylmethyl4( R)-dimethylcarbamoyl-2(S)- hydroxy-6-methyl-hept-6-enyl)-amide; quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; isoquinoline-4(R)-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide;

quinoline-3-carboxylic acid (4(R)-carbamoyl-1 (S)-cyclohexylmethyl- 2(S)-hydroxy-6-methyl-heptyl)-amide; quinoline-3-carboxylic acid (5-cyclohexyl-1 (S)-cyclohexylmethyl.2(S)-hydroxy-4( R)- methylcarbamoyl-pentyl)-amide; quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-6-methyl-4(S)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy4(R)- methylcarbamoyl-5-phenyl-pentyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy4(R)- methylcarbamoyl-5-phenyl-pentyl)-amide; quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-hydroxy-6-methyl- heptyl)-amide; quinoline-3-carboxyiic acid 1 (S)-benzyl-4(R)-cyclobutylcarbamoyl-2(S)-hydroxy-6- methyl-heptyl)-amide; quinoline-3-carboxylic acid 1(S)-benzyl-4(R)-benzylcarbamoyl-2(S)-hydroxy-6- methyl-heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl4(R)-cyclopropylcarbamoyl-2(S)-hydroxy-6- methyl-heptyl)-amide; quinoline-3-carboxy lic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(S)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl-4(R)-ethylcarbamoyl-2(S)-hydroxy-6-methyl- heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- propylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid [1-benzyl-2(S)-hydroxy-4(R)-(2(S)-hydroxy- ethylcarbamoyl)-6-methyl-heptyl]-amide; cinnoline-4(R)-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; isoquinoline4(R)-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl.heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methy Icarbamoy l-heptyi)-amide;

N-1(S)-Benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-hep tyl)-5-bromo- nicotinamide; quinoline-3-carboxylic acid 1 (R)-cyclohexylmethyl-2(R)-hydroxy-6-methyl-4(S)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid [1 -(4-benzyloxy-benzyl)-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide; quinoline-3-carboxylic acid [1-(4-benzyloxy-benzyl)-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide; isoquinoline-1 -carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoline-4(R)-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoline-6-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid [2(S)-hydroxy-1 -(4-hydroxy-benzyl)-6-methyl4( R)- methylcarbamoyl-heptyl]-amide; quinoline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl9(R)- methylcarbamoyl-heptyl)-amide; naphthaiene-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl-5-cyclohex-1 -enyl-2(S)-hydroxy4(R)- methylcarbamoyl-pentyl)-amide; quinoline-3-carboxylic acid [1-benzyl-2(S)-hydroxy-6-methyl-4(R)-(3-methyl- butylcarbamoyl)-heptyl]-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(S)- methylcarbamoyl-heptyl)-amide; trifluoro-methanesulfonic acid 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)- [(quinoline-3-carbonyl)-amino]-octyl)-ph ester; trifluoro-methanesulfonic acid 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)- [(quinoxaline-2-carbonyl)-amino]-octyl}-phenyl ester; quinoline-3-carboxylic acid 1 (S)-benzyl-5-cyclohexyl-2(S)-hydroxy9(R) methylcarbamoyl-pentyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide;

isoquinoline-3-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide; N-1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)-methylcarbamoyl -pentyl)-5-bromo- nicotinamide; quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-prop-2- ynylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-4(R)- hydroxycarbamoyl-6-methyl-heptyl)-amide; quinoline-3carboxylic acid 2(S)-hydroxy-1(S)-(4-methoxy-benzyl)-6-methyl4(R)- methylcarbamoyl-heptyl]-amide; isoquinoline-3carboxylic acid (5-cyclohexyl-1 (S)-cyclohexylmethyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide; 5-bromo-N-(Scyclohexyl-l (S)-cyclohexylmethyl-2(S)-hydroxy4(R)- methylcarbamoyl-pentyl)-nicotinamide; quinoxaline-2-carboxylic acid [2(S)-hydroxy-1 (S)-(4-methoxy-benzyl)-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide; isoquinoline4(R)-carboxylic acid (5-cyclohexyl-1 (S)-cyclohexylmethyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide; quinoline-2-carboxylic acid 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide; isoquinoline4(R)-carboxylic acid 1 (S)-benzyl-5-cyclohexyl-2(S)-hydroxy9(R) methylcarbamoyl-pentyl)-amide; quinoxaline-2-carboxylic acid [2(S)-hydroxy-1 (S)-(4-hydroxy-benzyl)-6-methyl4(R)- methylcarbamoyl-heptyl]-amide; quinoxaline-2-carboxylic acid (5-cyclohexyl-l (S)-cyclohexylmethy I-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide; quinoline-3-carboxylic acid [1 (S)-(4-chloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-(4-chloro-benzyl)-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide; quinoline-3-carboxylic acid 1 (S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-cyclohexylmethyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide;

quinoline-3-carboxylic acid [1 (S)-(4-chloro-benzyl)-5-cyclohexyl-2(S)-hydroxy4( R)- methylcarbamoyl-pentyl]-amide; q uinoxaline-2-carboxylic acid [1 (S)-(4-chloro-benzyl).5-cyclohexyl-2(S).hydroxy.

4(R)-methylcarbamoyl-pentyl]-amide; quinoline-2-carboxylic acid [1 (S)-(4-chloro-benzyl)-5-cyclohexyl-2(S)-hydroxy4(R)- methylcarbamoyl-pentyl]-amide; benzofuran-2-carboxyiic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; N-1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-hep tyl)-5,6-dichloro- nicotinamide; quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; N-1(S)-benzyl-2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-oct yl)-5-bromo- nicotinamide; 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methy I- 4(R)-methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)-amide; quinoline.2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)-amide; isoquinoline4(R)-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid [1 -(3,4-d ich ioro-benzy 1)-2(S)-hydroxy-6-methyl4( R )- methylcarbamoyl-heptyl]-amide; benzoIb]thiophene-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; 2-methyl-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-hepty l)-amide; 6, 7aimethoxy-quinoline-3-carboxyiic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; 6,7-difluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; 1 H-benzoimidazole-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4( R)- methylcarbamoyl-heptyl)-amide;

5-methyl-pyrazine-2-carboxylic acid 1(S)-benzy 1-2(S)-hydroxy-6-methyl4( R)- methylcarbamoyl-heptyl)-amide; quinoline-3-carboxylic acid [1 (S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl]-amide; quinoxaline-2-carboxylic acid [1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyi-hepty l]-amide; 5-chloro-1 H-indole-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7-methyl- octyl)-amide; 2-methoxy-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcabamoyl-heptyl)-amide; 5,6-dichloro-1 H-benzoimidazole-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6- methyl4(R)-methylcarbamoyl-heptyl)-amide; benzothiazole-2-carboxy lic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; 7,8-difluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide; 6,7,8-trifluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; 5,8-dimethyl-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methy Icarbamoy l-heptyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-butylcarbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; quinoline-3-carboxylic acid [1 (S)-(3,4-dichloro-benzyl)-2(S)-hydroxy-6-methyl4( R)- methylcarbamoyl-heptyl]-amide; 5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide; N-1(S)-benzyl-5-cyclopentyl-2(S)-hydroxy-4(R)-methylcarbamoy l-pentyl)-5-bromo- nicotinamide;

5,6,7,8-tetrahydro-quinoline-3-carboxylic acid 1 (S)-benzyl-5-cyclopentyl-2(S)- hydroxy-4(R)-methylcarbamoyl-pentyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-5-cyclopentyl-2(S)- hydroxy-pentyl)-amide; 6,7-dihydro-5H-[l ]pyrindine-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid [1(S)-(4,4-difluoro-cyclohexylmethyl)-2(S)-hydroxy-6- methyl4( R)-methylcarbamoyl-heptyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-(4,4-difluoro-cyclohexylmethyl)-2(S)-hydroxy-7- methyl-4(R)-methylcarbamoyl-octyl]-amide; quinoxaline-2-carboxylic acid I (S)-benzyl4( R)-ethylcarbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl4(R)- propylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid I (S)-benzyl-4(R)-cyclopropylcarbamoyl-2(S)-hydroxy- 7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4( R)-cyclobuty Icarbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid [1(S)-(4-difluoromethoxy-benzyl)-2(S)-hydroxy-7- methyl-4(R)-methylcarbamoyl-octyl]-amide; 4-{3(S)-hydroxy-7-methyl-5(R)-methylcarbamoyl-2(S)-[(quinoxa line-2-carbonyl)- amino]-octyl)-benzoic acid methyl ester; quinoxaline-2-carboxylic acid I (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-butyl)- amide; 6,7,8-trifluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; 6,7,8-trifluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy- 7-methyl-octyl)-amide; 6,8-difluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; 6,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-7 methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-butylcarbamoyl-5-cyclopentyl-2(S)- hydroxy-pentyl)-amide;

6-methyl-pyridine-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-8-methyl4(R)- methylcarbamoyl-nonyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4( R)-carbamoyl-2(S)-hydroxy-8-methyl- nonyl)-amide; quinoxaline-2-carboxylic acid 1(S)-biphenyl-4(R)-ylmethyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-7-methyl- oct-6-enyl)-amide; q uinoxaline-2-carboxylic acid (2(S)-hydroxy-6-methyl-4(R)-methylcarbamoyl-1 (S)- naphthalen-2-ylmethyl-heptyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-7,7- dimethyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7,7-dimethyl-4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl- pentyl)-amide; quinoxaline-2-carboxylic acid 1(S)-biphenyl-4(R)-ylmethyl-4(R)-carbamoyl-2(S)- hydroxy.7.methyl.octyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-5-(4,4-difluoro-cyclohexyl)-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4( R)-carbamoyl-5-(4,4-difluoro- cyclohexyl)-2(S)-hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-(3-fluoro-benzyl)-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3(S)-fluoro-benzyl)-2(S)- hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-oct-6-enyl)-amide; 6,7,8-trifluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl9(R)- methylcarbamoyl-nonyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-7-methyl- nonyl)-amide;

quinoxaline-2-carboxylic acid 1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-nonyl)- amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)dimethylcarbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy4(R)- methylcarbamoyl-5-phenyl-pentyl)-amide; 7,8-difluoro-quinoline-3-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl4(R)- methylcarbamoyl-octyl)-amide; 8-fluoro-q uinoline-3-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-2(S)-hydroxy4(R)-methylcarbamoyl-non- 6-enyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-non-6-enyl)- amide; 7,8 difluoro-quinoline-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; 8-fluoro-quinoline-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide; 4(S)hydroxy-2(R)-(3-methyl-butyl)-6-phenyl-5(S)-[(quinoxalin e-2(R)-carbonyl)- amino]-hexanoic acid; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-nonyl)- amide; 2-{2(S)-hydroxy-4-phenyl-3(S)-[(quinoxaline-2-carbonyl)-amin o]-butyl]-N1,N4- dimethyl-succinamide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4-ethylcarbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-butylcarbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid [7-fluoro-1 (S)-(4-fluoro-benzyl)-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl]-amide;

quinoxaline-2-carboxylic acid [4(R)-carbamoyl-l (S)-(3,4-dichloro-benzyl)-7-fluoro- 2(S)-hydroxy-7-methyl-octyl]-amide; 7,8-difluoro-quinoline-3-carboxylic acid [4(R)-carbamoyl-l (S)-(3,4-dichloro-benzyl)- 7-fluoro-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-1 (S)- phenethyl-octyl)-amide; 7,8-difluoro-quinoline-3-carboxylic acid [4(R)-carbamoyl-7-fluoro-l (S)-(4-fluoro- benzyl)-2(S)-hydroxy-7-methyl-octy l]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)- hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid {1(S)-[4(R)-(3-methyl-butyl)-5-oxo-tetrahydro-furan-2- yl]-2(S)-phenyl-ethyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(4- methyl-piperazine-1 -carbonyl)-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5- (tetrahydro-pyran4(R)-yl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl4( R )- (piperidine-1 -carbonyl)-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- (morpholine-4(R)carbonyl)-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(3- morpholin9-yl-propionyl)-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-3-(2-carbamoyl-indan-2-yl)-2(S)-hydroxy- propyl]-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-2(S)-hydroxy-4(R)-methylcarbamoyl-7- phenyl-hept-6-enyl)-amide; quinoline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; 6,7-dihydro-5H-[1 ]pyrindine-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7-fluoro- 2(S)-hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)- hydroxy-butyl)-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)- hydroxy-butyl)-amide;

quinoxaline-2-carboxylic acid (1 (S)-benzyl-4-carbamoyl-4(S)-cyclohexyl-2(S)- hydroxy-butyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4-carbamoyl-4(S)-cyclopentyl-2(S)- hydroxy-butyl)-amide; quinoline-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; N-1(S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl- octyl)-5-bromo- nicotinamide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl.I -(2(S)-fluoro-benzyl)-2(S)-hydroxy- 7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1 (S)-(2(S)-fluoro-benzyl)-2(S)- hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4(S)-(4- isopropyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl.2(S)-hydroxy-7-methyl-I (S)-thiophen- 2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S)-hydroxy-7-methyl-l (S)-thiazol- 4(R)-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4(S)- (3,3,5,5-tetramethyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid (1 ( S)-benzyl4(S)-carbamoy 1-2 (S)-hydroxy4( S)-indan- 2-yl-butyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4(S)-carbamoyl-4(S)-cycloheptyl-2(S)- hydroxy-butyl)-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-5-propyl- octyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-propyl- oct-5-enyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2, 7-dihydroxy-7-methyl- octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)- methylcarbamoyl-hept-6-enyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)- methylcarbamoyl-hept-6-enyl)-amide;

quinoxaline-2-carboxylic acid 1(S)-benzyl-6-chloro-2(S)-hydroxyS(S)- methylcarbamoyl-hept6-enyl)-amide; quinoxaline-2-carboxylic acid I (S)-benzyl-4(R)-carbamoyl-6-chloro-2(S)-hydroxy- hept6-enyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-6-cyclopropyl-2(S)- hydroxy-hexyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-6-cyclopropyl-2(S)-hydroxy-4(R)- methylcarbamoyl-hexyl)-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-4(S)-(4- methyl-cyclohexyl)-butylj-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy4(S)-indan- 2-yl-butyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(4- trifluoromethoxy-phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl-4(R)-carbamoyl-5-(4-fluoro-phenyl)-2(S)- hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy- hept-6-enyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7-chloro-2(S)-hydroxy- hept-6-enyl)-amide; 3-Hydroxy-quinoxaline-2-carboxy lic acid 1 (S)-benzy l4(R)carbamoyl.7.fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-benzylcarbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- [(pyridin-3-ylmethyl)-carbamoyl]-octyl}-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-8,8-trifluoro-2(S)-hydroxy-4(R)- methylcarbamoyl-7.trifluoromethyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-8,8-trifluoro-2(S)-hydroxy- 7-trifluoromethyl-octyl)-amide; quinoxaline-2-carboxylic acid [2(S)-hydroxy-7-methyl-4(R)-methylcarbamoyl-1 (S)-(4- methylcarbamoyl-benzyl)-octyl]-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-5-ethyl-2(S)-hydroxy- heptyl)-amide;

quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy4(S)- (tetrahydro-pyran-4-yl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- (2( R)-pyridin-2-yl-ethylcarbamoyl)-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-(3,4-dimethoxy-benzylcarbamoyl)-7- fluoro-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-6-methoxy- hexyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-chloro-2(S)-hydroxy oct-6-enyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-7-chloro-2(S)-hydroxy-4(R)- methylcarbamoyl-oct-6-enyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl4(R)-carbamoyl4(S)-(3,5-dimethyl- cyclohexyl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- [(pyridin-2-ylmethyl)-carbamoyl]-octyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-(4-hydroxy- phenyl)-ethylcarbamoyl]-7-methyl-octyl}amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)- ((thiophen-2-ylmethyl)-carbamoyl]-octylamide; quinoxaline-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-6-phenoxy- hexyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-6- isopropoxy-hexyl)-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-[2- (4-sulfamoyl-phenyl)-ethylcarbamoyl]-octyl}-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl4(R)- [(pyridin-4-ylmethyl)-carbamoyl]-octyl}-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl4-(2-ethylsu If anyl-ethylcarbamoyl)-7- fluoro-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyk7-fluoro-2(S)-hydroxy4(R)-(2-methoxy- ethylcarbamoyl)-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2- pyridin-3-yl-ethylcarbamoyl)-octyl]-amide;

quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2- pyrid in4(R)-y l-ethylcarbamoyl)-octyl].amide; quinoxaline-6-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid 1 (S)-benzyl-6-tert-butoxy4(R)-carbamoyl.2(S)- hydroxy-hexyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl4(R)-[2- 1(S)-methyl-1H-pyrrol-2-yl)-ethylcarbamoyl]-octyl}-amide; quinoxaline-2-carboxyiic acid [1 (S)-benzyl4(S)-carbamoyl4-(1,1 -dioxo-hexahydro- thiopyran-4-yl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2-(6- methoxy-l H-indol-3-yl)-ethylcarbamoyl]-7-methyl-octylfamide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy4(R)-(2-methoxy- benzylcarbamoyl)-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(3-methoxy- benzylcarbamoyl)-7-methyloctyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl-4(R)-(2- thiophen-2-yl-ethylcarbamoyl)-octyl]-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy4(R)-[2-( 1 H-indol- 3-yl)-ethylcarbamoyl]-7-methyl-octyl)-am quinoxaline-2-carboxylic acid (4(R)-[2-(4-amino-phenyl)-ethylcarbamoyl]-I (S)- benzyl-7-fluoro-2(S)-hyd roxy-7-methyl-octylkamide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4(R)-[2-(3 5-dimethoxy-phenyl)- ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methyl-octylWamide; quinoxaline-2-carboxylic acid {1(S)-benzyl-4(R)-[2-(3,4-dimethoxy-phenyl)- ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide; quinoxaline-2-carboxylic acid {1(S)-benzyl-7-fluoro-4(R)-[(furan-2-ylmethyl)- carbamoyl]-2(S)-hydroxy-7-methyl-octyl}-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4(R)-[2-(2,5aimethoxy-phenyl) ethylcarbamoyl]-7-fluoro-2(S)-hydroxy-7-methy l-octylkamide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(4-methoxy- benzylcarbamoyl)-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-6-cyclohexyloxy-2(S)- hydroxy-hexyl)-amide;

quinoxaline-2-carboxylic acid (4(R)-[(1 H-benzoimidazol-2-ylmethyl )-carbamoyl]-1(S)- benzyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl}-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2(S)- hydroxymethyi-pyrrolidine-l -carbonyl)-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-7-methyl4(R)- [(tetrahydrofuran-2-ylmethyl)-carbamoyl]-octyl}-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4-carbamoyl-4(S)-(4,4-difluoro- cyclohexyl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl4(R)-(2,3-d imethoxy-benzylcarbamoyl)-7- fluoro-2(S)-hydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [I (S)-benzylA(S)-carbamoyl4-(2,6-dimethyl- tetrahydro-pyran4-yl)-2(S)-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [4(R)carbamoyl-7-fluoro-l (S)-(3-fluoro-benzyl)-2(S)- hydroxy-7-methyl-octyl]-amide; 7,8-difluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; N-1 (S)-benzyl4( R)-carbamoyl-7-fluoro-2(S)-hydroxy.7-methyl-octyl)-5,6-dichl oro- nicotinamide; benzofuran-2-carboxylic acid 1 (S)-benzyl4( R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; cinnoline-4(R)-carboxylic acid 1 (S)-benzyl-4(R).carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-I -(4-iodo- benzyl)-7-methyl-octyl]-amide; pyrazine-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; 6,7,8-trifluoro-quinoline-3-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; quinoline-6-carboxylic acid 1 (S)-benzyl.4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide; isoquinoline-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide;

2-methoxy-quinoline-3-carboxylic acid 1 (S)-benzyl4(R)-carbamoyl-7.fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; 1 H-benzoimidazole-2-carboxylic acid 1 (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; benzothiazole-2-carboxylic acid 1 (S)-benzyl4(R)-carbamoy l-7.fluoro-2(S)-hydroxy- 7-methylsctyl)-amide; 5-methyl-pyrazine-2-carboxylic acid I (S)-benzyl-4(R)-carbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid I (S)-benzylA( R)-carbamoyl-2(S)-hydroxy-5-pyridin-3- yl-pentyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-cyclohexyl)-butyl]-amide; quinoline-3-carboxylic acid (1 (S)-benzyl4(S)-carbamoyl4-cyciohexyl-2(S)-hydroxy- butyl)-amide; quinoline-2-carboxylic acid (1(S)-benzyl4(S)-carbamoyl4-cyclohexyl-2(S)-hydroxy- butyl)-amide; fluoro-quinoline-3-carboxylic acid (1 (S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)- hydroxy-butyl)-amide; N-(1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-buty l)-5,6-dichloro- nicotinamide; N-(1(S)-benzyl-4(S)-carbamoyl-4-cyclohexyl-2(S)-hydroxy-buty l)-5-bromo- nicotinamide; quinoxaline-2-carboxylic acid (4( R)-carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-1 - phenyl-octyl)-amide; quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-pyridin-2- yl-pentyl)-amide; quinoxaline-2-carboxylic acid [4( R)-carbamoyl-2(S)-hydroxy4-( l-hydroxy- cyclohexyl)-l (S)-thiophen-2-ylmethyl-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(4- hydroxy-tetrahydro.thiopyran-4-yl)-butyl]-amide; 1,3-dimethyl-1 H-pyrazolo[3,4-b]pyridine-5-carboxylic acid I (S).benzyl4(R)- carbamoyl-7-fluoro-2(S)-hydroxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)- hydroxycarbamoyl-7-methyl-octyl)-amide;

quinoxaline-2-carboxylic acid (1(S)-benzyl-7-fluoro-2(S)-hydroxy-4(R)- methoxycarbamoyl-7-methyl-octyl)-amide; 7,8-difluoro-quinoline-3-carboxylic acid (1 (S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy- 5-phenyl-pentyl)-amide; quinoxaline-2-carboxylic acid [I (S)-benzyl4(R)-carbamoyl-5-(2-chloro-phenyl)-2(S)- hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-5-o-tolyl- pentyl)-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-2(S)-hydroxy4(R)-hydroxycarbamoyl-5- phenyl-pentyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-cyclopentyl)-butyl]-amide; quinoxaline-2-carboxylic acid [I (S)-benzyl4(S)-carbamoyl-2(S)-hydroxy4-( 1 - hydroxy-4-methyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-5-(3,4-dichloro-phenyl)- 2(S)-hyd roxy-pentylj-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl4(R)-carbamoyl-5-(2-fluoro-phenyl)-2( S)- hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4- (1 -hydroxy-cyciopentyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-3-methyl-cyclopentyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxy4(S)-hyd roxycarbamoyl4- (1-hydroxy-4-methyl-cyclohexyl)-butyl]-amide; N-(1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-phenyl-pentyl)- 5-bromo- nicotinamide; 8-Fluoro-quinoline-3-carboxylic acid (1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-5-phenyl- pentyl)-amide; 6,7-dihydro-SH-[l )pyrindine-3-carboxylic acid (1 (S)-benzyl4(R)-carbamoyl-2(S)- hydroxy-5-phenyl-pentyl)-amide; quinoline-3-carboxylic acid (1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-5-phenyl- pentyl)-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-3,5-dimethyl-cyclohexyl)-butyl]-amide;

q uinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hyd roxy-4(S)-hydroxycarbamoyl-4- (1-hydroxy-3,5-dimethyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy-cycloheptyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxyA(S).hydrnxycarbamoylA.

(1 -hydroxy-cycloheptyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl4(R)-carbamoyl-5-(3-fluoro-phenyl)-2(S)- hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-m-tolyl- pentyl)-amide; quinoxaline-2-carboxylic acid (1(S)-benzyl-2(S)-hydroxy4-isobutylcarbamoyl-butyl)- amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(2- hydroxy-adamantan-2-yl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(9- hydroxy-bicyclo[3. 3.1 ]non-9-yl)-butyl]-amide; quinoxaline-2-carboxylic acid [I (S)-benzyl-2(S)-hydroxy4(S)-(2.hydroxy- adamantan-2-yl)4-hydroxycarbamoyl-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxy-4(S)-(9-hydroxy- bicyclo[3.3.1]non-9-yl)4-hydroxycarbamoyl-buty lJ-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(R)-carbamoyl-2(S)-hydroxy-5-(3- methoxy-phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy4-propyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-2(S)-hydroxy-4(S)-hydroxycarbamoyl-4- (1 -hydroxy4-propyl-cyclohexyl)-butyl]- amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl4(R)-carbamoyl-2(S)-hydroxy-5-(4- methoxy-phenyl)-pentyl]-amide; q uinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-4(S)-(4-ethyl-1 -hydroxy- cyclohexyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy4 ,4-dimethyl-cyclohexyl)-butyl]-amide; quinoxaline-2-carboxylic acid [1 (S)-benzyl-2(S)-hydroxy4(S)-hydroxycarbamoyl4- (1-hydroxy-4,4-dimethyl-cyclohexyl)-but yl]-amide;

quinoxaline-2-carboxylic acid [1 (S)-benzyl-4(S)-carbamoyl-4-(4,4-difluoro-1 -hydroxy- cyclohexyl)-2-hydroxy-butyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3-fluoro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(3,5-difluoro-benzyl)-2(S),7- dihyd roxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid 4(R)-carbamoyl-l (S)-(3-chloro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-(3-chloro-benzyl)-2(S),7-dihydroxy-4(R)- hydroxycarbamoyl-7-methyl-octyl]-amide; 7,8-Difluoro-quinoline-3-carboxylic acid (1 S)-benzyl4(R)-carbamoyl-2(S), 7- dihydroxy-7-methyl-octyl)-amide; 6,7,8-Trifluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-carbamoyl-2(S),7- dihyd roxy-7-methyl-octyl)-amide; quinoxaline-2-carboxylic acid [1 (S)-(3,5-difluoro-benzyl)-2(S),7-dihydroxy4(R)- hydroxycarbamoyl-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (1 (S)-benzyl-2(S),7-dihydroxy-4(R)-hydroxycarbamoyl- 7-methyl-octyl)-amide; 7,8-Difluoro-quinoline-3-carboxylic acid (1(S)-benzyl-4(R)-ethylcarbamoyl-2(S),7- d ihyd roxy-7-methyl-octyl)-amide; N-(1(S)-Benzyl-4(R)-carbamoyl-2(S),7-dihydroxy-7-methyl-octy l)-4-trifluoromethyl- nicotinamide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1(S)-(2-chloro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]-amide; 7,8-Difluoro-quinoline-3-carboxylic acid [(4R)carbamoyl-l (S)-(3-fluoro-benzyl)- 2(S),7-dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-(2-fluoro-benzyl)-2(S),7-dihydroxy-4(R)- hydroxycarbamoyl-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S),7-dihydroxy-7-methy (S)- thiophen-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1 (S)-(2-fluoro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid [1(S)-(3,4-difluoro-benzyl)-2(S),7-dihydroxy-4(R)- hyd roxycarbamoyl.7-methyl-octyl].amide;

quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1 (S)-(3,4-difluoro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S),7-dihydroxy-7-methy (S)- naphthalen-l -ylmethyl-octyl)-amide; 6,7,8-Trifluoro-quinoline-3-carboxylic acid [4(R)-carbamoyl-1 (S)-(3-fluoro-benzyl)- 2(S),7-dihydroxy-7-methyl-octyl]-amide; quinoxaline-2-carboxylic acid (4(R)-carbamoyl-2(S),7-dihydroxy-7-methyl-1 (S)- naphthalen-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid (2(S),7-dihydroxy-4(R)-hydroxycarbamoyl-7-methyl- 1 (S)-naphthalen-2-ylmethyl-octyl)-amide; quinoxaline-2-carboxylic acid (1(S)-benzo[b]thiophen-3-ylmethyl-4(R)-carbamoyl- 2(S),7-dihydroxy-7-methylsctyl)-amide; quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-5-(4-hydroxy- phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-5-(3-hydroxy- phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-5-(2-hydroxy- phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-5-(2-hydroxy-5- methyl-phenyl)-pentyl]-amide; q uinoxaline-2-carboxyiic acid [1 -benzyl-4-carbamoyl-2-hydroxy-5-(2-hydroxy-3- methyl-phenyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl4-carbamoyl-5-(3-ethoxy-2-hydroxy-phenyl)- 2-hydroxy-pentyl]-amide; quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2-hydroxy-5-(4-hydroxy-3,5- dimethyl-phenyl)-pentylj-amide; quinoxaline-2-carboxylic acid (1-benzyl4-carbamoyi-2,6-dihydroxy-6-methyl-heptyl)- amide; quinoxaline-2-carboxylic acid [1 -benzyl4-carbamoyl-2-hyd roxy-5-( 1 -hydroxy- cyclohexyl)-pentyl]-amide; quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-(4,4-difluoro-1-hydroxy-cyclohexyl)- 2(S)-hydroxyS-hydroxycarbamoyl-but yl]-amide; and quinoxaline-2-carboxylic acid [1(S)-benzyl-4(S)-carbamoyl-2(S)-hydroxy-4-(1- hydroxy4-trifluoromethyl-cyclohexyl)-butyl]-amide.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis). in a mammal, preferably a human, comprising an amount of a compound of the formula I or a pharmaceutically acceptable salt thereof effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by inhibiting MIP-la binding to the receptor CCR1 in a mammal, preferably a human, comprising an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, effective in treating or preventing such disorder or condition and a pharmaceutically acceptable carrier. Examples of such disorders and conditions are those enumerated in the preceding paragraph.

The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

The present invention also relates to a method for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or

prevention an amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, that is effective in treating or preventing such disorder or condition.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula I, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a pharmaceutical composition for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal, preferably a human, comprising a CCR1 receptor antagonizing effective amount of a compound of the formula 1, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

The present invention also relates to a method for treating or preventing a disorder or condition selected from autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis) in a mammal, preferably a human, comprising administering to a mammal in need of such treatment or prevention a CCR1 receptor antagonizing effective amount of a compound of formula I, or a pharmaceutically acceptable salt thereof.

This invention also encompasses pharmaceutical compositions containing and methods of treating or preventing comprising administering prodrugs of compounds of the

formula I. Compounds of formula I having free amino, amido, hydroxy or carboxylic groups can be converted into prodnrgs. Prodrugs include compounds wherein an amino acid residue, or a polypeptide chain of two or more (e.g., two, three or four) amino acid residues which are covalently joined through peptide bonds to free amino, hydroxy or carboxylic acid groups of compounds of formula I. The amino acid residues include the 20 naturally occurring amino acids commonly designated by three letter symbols and also include, 4-hydroxyproline, hydroxylysine, demosine, isodemosine, 3-methylhistidine, norvalin, beta-alanine, gamma- aminobutyric acid, citrulline homocysteine, homoserine, ornithine and methionine sulfone.

Prodrugs also include compounds wherein carbonates, carbamates, amides and alkyl esters which are covalently bonded to the above substituents of formula I through the carbonyl carbon prodrug sidechain. Prodrugs also include compounds of formula I in which the secondary amide and its hydroxy when taken together form a group of the formula wherein R', R2 , R3, R4 and R5 are as defined in formula I and U and V are independently carbonyl, methylene, SO2 or SO3, and b is an integer from one to three wherein each methylene group is optionally substituted with hydroxy.

Detailed Description of the Invention Compounds of the formula I may be prepared according to the following reaction schemes and discussion. Unless otherwise indicated g, n, m, p, and R1 through R6 and structural formula I in the reaction Schemes and discussion that follow are as defined above.

SCHEME 1

Scheme 1 refers to the preparation of compounds of the formula I having the exact stereochemistry Compounds of the formula la and Ib, or any of the intermediates thereof, can be separated by column chromatography according to methods well known to those of ordinary skill in the art, to yield pure compounds of the formula la and lb.

Referring to Scheme 1, compounds of the formula I, wherein either or both R4or R5 are other than hydrogen, are prepared from compounds of the formula Il (i.e. lia and llb) by reaction with a compound of the formula R4RsNH in a polar solvent at a temperature from about 0°C to about 10000, preferably the boiling point of the solvent used, i.e. 65"C when methanol is the solvent. Suitable solvents include, alcohols, such as methanol, ethanol, or butanols or ethers such as glyme or dioxane (an acid catalyst is preferably used with an ether solvent). Preferably the solvent is dioxane.

Alternatively, compounds of formula I, wherein either or both R4 and R5 are hydrogen, can be prepared from compounds of formula II, (i.e. Ila and llb) by reaction with ammonia or another volatile amine in a polar solvent at a temperature from about -10°C to about 35"C, preferably at about 30°C. Suitable solvents include, alcohols, such as methanol, ethanol, or butanols; or ethers such as glyme or dioxane (an acid catalyst may be used with an ether solvent). Preferably the solvent is methanol.

Compounds of formula ll are prepared by coupling a compound of formula Ill (i.e.

Illa and Illb) with an acid of the formula R'CO2H. Such a coupling reaction is generally conducted at a temperature of about -30°C to about 80"C, preferably about 0°C to about 25°C. Examples of suitable coupling reagents which activate the carboxylic acid functionality are dicyclohexylcarbodiimide/hydroxybenzotriazole (DCC/HBT), N-3- dimethylaminopropyl-N'-ethylcarbodiimide (EDC)/HBT, 2-ethyoxy-1 -ethoxycarbonyl-I ,2- dihydroquinoline (EEDQ), carbonyl diimidazole (CDl)/dimethylaminopyridine (DMAP), and diethylphosphorylcyanide. The coupling is conducted in an inert solvent, preferably an

aprotic solvent, such as acetonitirile, dichloromethane, chloroform, and dimethylformamide.

The preferred solvent is dichloromethane.

For a discussion of other conditions used for amide coupling see Houben-Weyl, Vol.

XV, part II, E. Wunsch, Ed., George Theime Veriag, 1974, Stuttgart, and those described in M. Bodanszky. Principles of Peptide Synthesis, Springer-Verlag, Berlin (1984) and The Peptides. Analvsis. Svnthesis and Biology (ed. E. Gross and J. Meienhofer), Vois 1-5.

(Academic Press, New York) 1979-1983.

The compounds of formula Ill, wherein R3 is (C,-C10)alkyl, (C3-C10)cycloalkyl-(CH2)n-l (C2-C8)heterocycloalkyl-(CH2)n-, (C2-Cg)heteroaryl-(CH2)n-, or aryl-(CH2)n- can be prepared by deprotection of compounds of the formula IV (i.e. IVa and IVb). Suitable protecting groups, of the formula P, include carbobenzyloxy, t-butoxy carbonyl or 9-fluorenyl- methylenoxy carbonyl.

For example: (a) If the protecting group, P, of the compound of the formula IV is carbobenzyloxy, the latter may be removed by hydrogenation with a nobel metal catalyst such as palladium or palladium hydroxide on carbon in the presence of hydrogen. The hydrogenation is generally conducted at a temperature of about 0°C to about 10000, preferably about 20°C to 50°C.

(b) If the protecting group, P, is t-butoxycarbonyl group, such group may be removed by acidolysis. Acidolysis may be conducted with HCI in dioxane or with trifluoracetic acid in methylene chloride at a temperature of about -30°C to about -70°C, preferably about -5°C to about 35°C.

(c) If the protecting group, P, is 9-fluorenylmethylenoxycarbonyl, such group may be removed by treatment with an amine base, preferably piperidine. This reaction may be run in piperidine as solvent at 1000 to about 10000, preferably at 25°C.

Compounds of the formula III, wherein R3 is substituted (C1-C,0)alkyl, (C3- C0)cycloalkyl-(CH2)n- or (C2-Cg)heterocycloalkyl-(CH2)n- may be prepared from compounds of the formula IV, wherein R3 is (C1-C10)alkyl, (C3-C,0)cycloalkyl-(CH2)n- or (C2- Cg)heterocycloalkyl-(CH2)n-, wherein one of the carbon-carbon single bonds is replaced by a carbon-carbon double bond, by methods well known to those of ordinary skill in the art.

Specifically, one example of introduction of substitution into the R3 group, a compound of formula lil, wherein R3 is (C,-C10)alkyl substituted by one to three fluoro groups can be prepared from compounds of the formula IV, wherein R3 is (01.010)alkyl, wherein one of the carbon-carbon single bonds of said (C,-C,0)alkyl has been replaced by a carbon-carbon double bond, by reaction with hydrogen fluoride in pyridine (i.e. pyridinium poly(hydrogen

fluoride), in a reaction inert solvent. Suitable solvents include cyclohexane, toluene or benzene, preferably benzene. The aforesaid reaction is run at a temperature from about - 78"C to about 35"C. Preferably, this reaction is carried out in benzene at about 25"C.

Compounds of the formula IV , wherein R3 is (C1-C10)alkyl, (C3-C,O)cycloalkyl- (CH2)n-, (C2-Cg)heterocycloalkyl-(CH2)n-, (C2-Cg)heteroaryl-(CH2)n- or aryl-(CH2)n-, wherein n is other than zero, can be prepared by reaction of a compound of formula V with a compound of the formula R3-L, wherein L is a leaving group, in the presence of a strong base in an aprotic polar solvent. Suitable leaving groups include chloro, fluoro, bromo, iodo, mesylate, triflate or tosylate. Preferably, the leaving group is a triflate, iodide or bromide.

Triflates may be easily prepared according to the method of Beard, metal., J Org Chem., 38.

3673 (1973). Suitable bases include lithium dialkyl amides such as lithium N-isopropyl-N- cyclohexylamide or potassium hydride. Suitable solvents include ethers (such as THF, glyme or dioxane) benzene or toluene, preferably THF. The aforesaid reaction is conducted at about -78°C to about 0°C, preferably at about -78°C.

Alternatively, compounds of the formula IV, wherein R3 is (C,-C,O)alkyl, (C3- C,O)cycloalkyl-(CH2)n- or (C2-Cg)heterocycloalkyl-(CH2)n- can be prepared by reaction of a compound of formula V with an aldehyde or ketone precursor of R3 in an aldol condensation.

For example, a compound of the formula V can be reacted with a compound of the formula R3(=0) in the presence of a base, to form an aldol intermediate of the formula which may be isolated and taken on to final product or converted directly in the same reaction step to a compound of the formula IV by the loss of water. The degree of completion for the conversion of compounds of the formula II to the aldol product of formula I may be assessed using one or more analytical techniques, such as thin layer chromatography (tic) or mass spectrometry. In some instances it may be possible or desirable to isolate the intermediate of formula VI. In such case, the compound of formula VI may be converted into the compound of formula IV by the elimination of water using techniques which are familiar to those skilled in the art, for example, by heating to the reflux temperature a solution of the compound of formula VI

in a solvent such as benzene, toluene or xylene, in the presence of a catalytic amount of phosphorous pentoxide, benzene- or p-toluenesulfonic acid with provision for the removal of the water generated, preferably (methoxycarbonylsulfamoyl).triethylammonium hydroxide (Burgess reagent). Such water removal techniques may involve the use of molecular sieves or a Dean-Stark trap to isolate the water created as an azeotrope with the solvent.

The aldol reaction is typically carried out in a polar solvent such as DMSO, DMF, tetrahydrofuran (THF), methanol or ethanol, at a temperature from about -78°C to about 80°C.

Preferably, this reaction is carried out in THF at about -78°C. Suitable bases for use in the aldol formation step include potassium carbonate (K2CO3), sodium carbonate (Na2CO3), sodium hydride (NaH), sodium methoxide, potassium-tert.-butoxide, lithium diisopropylamide, pyrrolidine and piperidine. Lithium diisopropylamide is preferred. Aldol condensations are described in "Modem Synthetic Reactions," Herbert O. House, 2d. Edition, W.A. Benjamin, Menlo Park, California, 629-682 (1972), J. Ora. Ohem 49 2455 (1984), and Tetrahedron, 38 (20), 3059 (1982).

Compounds of the formula IV wherein R3 is unsaturated can be converted to saturated analogues by hydrogenating the compounds containing a carboncarbon double bond, using standard techniques that are well known to those skilled in the art. For example, reduction of the double bond may be effected with hydrogen gas (H2), using catalysts such as palladium on carbon (Pd/C), palladium on barium sulfate (Pd/BaSO4), platinum on carbon (Pt/C), or tris(triphenylphosphine) rhodium chloride (Wilkinson's catalyst), in an appropriate solvent such as methanol, ethanol, THF, dioxane or ethyl acetate, at a pressure from about 1 to about 5 atmospheres and a temperature from about 1000 to about 60"C, as described in Catalytic Hydrogenation in Organic Synthesis, Paul Rylander, Academic Press Inc., San Diego, 3163 (1979). The following conditions are preferred: Pd on carbon, methanol at 25°C and 50 psi of hydrogen gas pressure. This method also provides for introduction of hydrogen isotopes ( deuterium, tritium) by replacing 1H2 with 2H2 or 3H2 in the above procedure.

An altemative procedure employing the use of reagents such as ammonium formate and Pd/C in methanol at the reflux temperature under an inert atmosphere (e.a., nitrogen or argon gas) is also effective in reducing the carbon-carbon double bond of compounds of the formula I. Another altemative method involves selective reduction of the carboncarbon bond.

This can be accomplished using samarium and iodine or samarium iodide (semi2) in methanol or ethanol at about room temperature, as described by R. Yanada Ae. al., Synlett., 4434 (1995).

Compounds of the formula V can be prepared by methods well known to those of ordinary skill in the art or are commercially available. Specifically, compounds of the formula

Va and Vb (shown below) can be prepared by the method of Fray et al., (J. Ora. Chem., 48284833 (1986)) using an (S)-aldehyde of the formula Compounds of the formula VII are prepared by reducing amino acids or amino esters to alcohols (Stanfield et al., J. Org. Them. 46, 47994800 (1981), Soai et al., Bull. Chem. Soc.

Jpn., 57, 2327 (1984)) followed by oxidation of the alcohols to aldehydes of the formula VII (Luly et al., J.Org. Chem., 53 (26), 6109-6112 (1988) and Denis et al., J Org. Chem., 56 (24), 6939-6942 (1991).). Un-natural amino acids can be prepared according to the method of Myers et al., Tet. Lett. 36, (1995) and Myers et al. J. Am. Chem. Soc., 117, 8488-8489 (1995).

Alternatively, compounds of the formula V can also be made by the method of DeCamp et al., (Tetrahedron Lett., 32, 1867 (1991)).

Compounds of the formula I, with the exact stereochemistry can be prepared according to the methods of Scheme 1, using either the minor lactone diastereomer of the formula, which can be prepared by the method of Fray, suDra, from the (S)-aldehyde, or the alternate diastereomeric pair of the formula

which can be prepared using the corresponding (R)-aldehyde according to the method of Fray, supra.

Aldehyde or ketone precursors of the group R3 are commercially available (e.g., cyclohexanone) or can be made by methods well known to those of ordinary skill in the art, such as described in J. Am. Them. Soc., 9e, 7001 (1968) and J Org. Chem., 4Q, 574 (1975).

Unless indicated otherwise, the pressure of each of the above reactions is not critical. Generally, the reactions will be conducted at a pressure of about one to about three atmospheres, preferably at ambient pressure (about one atmosphere).

The compounds of the formula I which are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate a compound of the formula I from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent, and subsequently convert the free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is obtained.

The acids which are used to prepare the pharmaceutically acceptable acid addition salts of the base compounds of this invention are those which form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions, such as hydrochloride, hydrobromide, hydroiodide, nitrate, sulfate or bisulfate, phosphate or acid phosphate, acetate, lactate, citrate or acid citrate, tartrate or bitartrate, succinate, maleate, fumarate, gluconate, saccharate, benzoate, methanesulfonate and pamoate [iLI 1,1 '-methylene-bis- (2-hydroxy-3-naphthoate)l salts.

Those compounds of the formula I which are also acidic in nature, are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and

potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the herein described acidic compounds of formula I. These non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium, calcium and magnesium, etc.

These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure.

Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum product yields.

Compounds of the formula I and their pharmaceutically acceptable salts (hereinafter also referred to, collectively, as "the active compounds") are potent antagonists of the CCR1 receptors. The active compounds are useful in the treatment or prevention of autoimmune diseases (such as rheumatoid arthritis, type I diabetes (recent onset), inflammatory bowel disease, optic neuritis, psoriasis, multiple sclerosis, polymyalgia rheumatica, uveitis, and vasculitis), acute and chronic inflammatory conditions (such as osteoarthritis, adult respiratory distress syndrome, Respiratory Distress Syndrome of infancy, ischemia reperfusion injury, and glomerulonephritis), allergic conditions (such as asthma and atopic dermatitis), infection associated with inflammation (such as viral inflammation (including influenza and hepatitis) and Guillian-Barre), transplantation tissue rejection, atherosclerosis, restenosis, HIV infectivity (co-receptor usage), and granulomatous diseases (including sarcoidosis, leprosy and tuberculosis).

The activity of the compounds of the invention can be assessed according to procedures know to those of ordinary skill in the art. Examples of recognized methods for determining CCR1 induced migration can be found in Coligan, J. E., Kruisbeek, A.M., Margulies, D.H., Shevach, E.M., Strober, W. editors: Current Protocols In Immunology, 6.12.1- 6.12.3. (John Wiley and Sons, NY, 1991). One specific example of how to determine the activity of a compound for inhibiting migration is described in detail below.

Chemotaxis Assay: The ability of compounds to inhibit the chemotaxis to various chemokines can be evaluated using standard 48 or 96 well Boyden Chambers with a 5 micron polycarbonate filter. All reagents and cells can be prepared in standard RPMI (BioWhitikker Inc.) tissue

culture medium supplemented with 1 mg/ml of bovine serum albumin. Briefly, MIP-la (Peprotech, Inc., P.O. Box 275, Rocky Hill NJ) or other test agonists, were placed into the lower chambers of the Boyden chamber. A polycarbonate filter was then applied and the upper chamber fastened. The amount of agonist chosen is that determined to give the maximal amount of chemotaxis in this system (e.g., 1 nM for MIP-1« should be adequate).

THP-1 cells (ATCC TIB-202), primary human monocytes, or primary lymphocytes, isolated by standard techniques can then be added to the upper chambers in triplicate together with various concentrations of the test compound. Compound dilutions can be prepared using standard serological techniques and are mixed with cells prior to adding to the chamber.

After a suitable incubation period at 37 degrees centigrade (e.g. 3.5 hours for THP-1 cells, 90 minutes for primary monocytes), the chamber is removed, the cells in the upper chamber aspirated, the upper part of the filter wiped and the number of cells migrating can be determined according to the following method.

For THP-1 cells the chamber (a 96 well variety manufactured by Neuroprobe) can be centrifuged to push cells off the lower chamber and the number of cells can be quantitated against a standard curve by a color change of the dye fluorocein diacetate.

For primary human monocytes, or lymphocytes, the filter can be stained with Dif Quik dye (American Scientific Products) and the number of cells migrating can be determined microscopically.

The number of cells migrating in the presence of the compound are divided by the number of cells migrating in control wells (without the compound). The quotant is the % inhibition for the compound which can then be plotted using standard graphics techniques against the concentration of compound used. The 50% inhibition point is then determined using a line fit analysis for all concentrations tested. The line fit for all data points must have an coefficient of correlation (R squared) of > 90% to be considered a vaiid assay.

All of the compounds of the invention that were tested had IC 50 of less than 25SaM, in the Chemotaxis assay.

The compositions of the present invention may be formulated in a conventional manner using one or more pharmaceutically acceptable carriers. Thus, the active compounds of the invention may be formulated for oral, buccal, intranasal, parenteral (e.g., intravenous, intramuscular or subcutaneous) or rectal administration or in a form suitable for administration by inhalation or insufflation. The active compounds of the invention may also be formulated for sustained delivery.

For oral administration, the pharmaceutical compositions may take the form of, for example, tablets or capsules prepared by conventional means with pharmaceutically acceptable excipients such as binding agents (e.g., pregelatinized maize starch polyvinylpyrrolidone or hydroxypropyl methylcellulose); fillers (e.g., lactose, microcrystalline cellulose or calcium phosphate); lubricants (e.g., magnesium stearate, talc or silica); <BR> <BR> <BR> disintegrants (, potato starch or sodium starch glycolate); or wetting agents (e.g., g, sodium lauryl sulphate). The tablets may be coated by methods well known in the art. Liquid preparations for oral administration may take the form of, for example, solutions, syrups or suspensions, or they may be presented as a dry product for constitution with water or other suitable vehicle before use. Such liquid preparations may be prepared by conventional means with pharmaceutically acceptable additives such as suspending agents (erg, sorbitol syrup, methyl cellulose or hydrogenated edible fats); emulsifying agents (, lecithin or acacia); non-aqueous vehicles (, almond oil, oily esters or ethyl alcohol); and preservatives (, methyl or propyl p-hydroxybenzoates or sorbic acid).

For buccal administration, the composition may take the form of tablets or lozenges formulated in conventional manner.

The active compounds of the invention may be formulated for parenteral administration by injection, including using conventional catheterization techniques or infusion. Formulations for injection may be presented in unit dosage form, e.g., in ampules or in multi-dose containers with an added preservative. The compositions may take such forms as suspensions, solutions or emulsions in oily or aqueous vehicles, and may contain formulating agents such as suspending, stabilizing and/or dispersing agents. Alternatively the active ingredient may be in powder form for reconstitution with a suitable vehicle, e.g., sterile pyrogen-free water, before use.

The active compounds of the invention may also be formulated in rectal compositions such as suppositories or retention enemas, e.g., containing conventional suppository bases such as cocoa butter or other glycerides.

For intranasal administration or administration by inhalation, the active compounds of the invention are conveniently delivered in the form of a solution or suspension from a pump spray container that is squeezed or pumped by the patient or as an aerosol spray presentation from a pressurized container or a nebulizer, with the use of a suitable propellant, e.g., dichlorodifluoromethane, trichlorofluoromethane, dichlorotetrafluoroethane, carbon dioxide or other suitable gas. In the case of a pressurized aerosol, the dosage unit may be determined by providing a valve to deliver a metered amount. The pressurized container or nebulizer may contain a solution or suspension of the active compound.

Capsules and cartridges (made, for example, from gelatin) for use in an inhaler or insufflator may be formulated containing a powder mix of a compound of the invention and a suitable powder base such as lactose or starch.

A proposed dose of the active compounds of the invention for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above (, rheumatoid arthritis) is 0.1 to 1000 mg of the active ingredient per unit dose which could be administered, for example, 1 to 4 times per day.

Aerosol formulations for treatment of the conditions referred to above (g;, rheumatoid arthritis) in the average adult human are preferably arranged so that each metered dose or "puff" of aerosol contains 20 g to 1000 g of the compound of the invention. The overall daily dose with an aerosol will be within the range 0.1 mg to 1000 mg.

Administration may be several times daily, for example 2, 3, 4 or 8 times, giving for example, 1, 2 or 3 doses each time.

The active agents can be formulated for sustained delivery according to methods well known to those of ordinary skill in the art. Examples of such formulations can be found in United States Patents 3,538,214, 4,060,598, 4,173,626, 3,119,742, and 3,492,397.

The compounds of the invention can also be utilized in combination therapy with other therapeutic agents such as with immunosuppressant agents such as cyclosporin A and FK-506, Cellceptl3), rapamycin, leuflonamide or with classical anti-inflammatory agents (e.g. cyclooxygenase/lipoxegenase inhibitors) such as tenidap, aspirin, acetaminophen, naproxen and piroxicam, steroids including prednisone, azathioprine and biological agents such as OKT-3, anti IL-2 monoclonal antibodies (such as TAC),.

The following Examples illustrate the preparation of the compounds of the present invention. Melting points are uncorrected. NMR data are reported in parts per million (6) and are referenced to the deuterium lock signal from the sample solvent (deuteriochloroform unless otherwise specified). Commercial reagents were utilized without further purification.

THF refers to tetrahydrofuran. DMF refers to N, N-dimethylformamide. Chromatography refers to column chromatography performed using 32-63 mm silica gel and executed under nitrogen pressure (flash chromatography) conditions. Low Resolution Mass Spectra (LRMS) were recorded on either a Hewlett Packard 5989, utilizing chemical ionization (ammonium), or a Fisons (or Micro Mass) Atmospheric Pressure Chemical lonization (APCI) plafform which uses a 50/50 mixture of acetonitrile/water with 0.1% formic acid as the ionizing agent. Room or ambient temperature refers to 20-25°C. All non-aqueous reactions were run under a nitrogen atmosphere for convenience and to maximize yields.

Concentration at reduced pressure means that a rotary evaporator was used. The names

for the compounds of the invention were created by the Autonom 2.0 PC-batch version from Beilstein Informationssysteme GmbH (ISBN 3-89536-976-4).

EXAMPLE 1 QUINOLINE-3-CARBOXYLIC ACID (1 (S)-CYCLOHEXYLMETHYL-2(S)- HYDROXY-6-METHYLA(R)-METHYLCARBAMOYL-HEPTYL-6-ENYL)-AMlDE METHOD A QUINOLINE-3-CARBOXYLIC ACID (1 -[4-(2-METHYLPROPEN-2-YL)-5-OXO- TETRAHYDROFURAN-2-YL]-2-CYCLOHEXYL-ETHYL}-AMIDE To a solution of 1-{4-(2-methylpropen-2-yl)-[5-oxo-tetrahydrofuran-2-yl]-2- cyclohexyl-ethyl)-carbamic acid tert-butyl ester (302 mg, 0.83 mmol)(prepared according to the method of Fray, supra, except that (S)-2-(tert-butoxycarbonylamino)-3-cyclohexyi-1- propionaldehyde is the starting material aldehyde) in 15 mL of methylene chloride was added 1.5 mL of trifluoroacetic acid. The mixture was stirred at room temperature under a nitrogen atmosphere for 2 hours at which time the solvent was removed by azeotropic distillation under reduced pressure, using toluene as a cosolvent during the distillation. The resulting crude oil was dissolved in methylene chloride (5 mL) and quinoline-3-carboxylic acid (219 mg, 1.26 mmol), hydroxybenzotriazole (HOBT)(188 mg, 1.39 mmol), triethylamine (0.25 mL, 1.80 mmol) and N-3-dimethylaminopropyl-N'-ethylcarbodiimide (EDC)(248 mg, 1.29 mmol) was added. The resulting mixture was stirred at room temperature for 16 hours.

The solution was transferred to a separatory funnel with 15 mL of methylene chloride and washed with 10% citric acid, saturated sodium bicarbonate and brine. The organic layer was dried over sodium sulfate and the solvent removed in vacuo. The remaining crude oil was purified by silica gel chromatography eluting with 3:1 hexanes: ethyl acetate to provide quinoline-3-carboxylic acid {1(S)-[4(R)-(2-methylpropen-2-yl)-5-oxo-tetrahydrofuran-2(S) -yl]- 2-cyclohexyl-ethyl)-amide as a white foam (236 mg, 67%).

LRMS: 421 (MH+); 1H NMR (300 MHz, CDC13): 6 0.90-1.89 (m, 13H), 1.63 (s, 3H), 2.03-2.14 (m, 2H), 2.38 (m, 2H), 2.48 (d, 1H, J=14.6 Hz), 2.73 (m, 1H), 4.63 (m, 2H), 4.69 (s, 1H), 4.79 (s, 1H), 6.9 (brs, 1H), 7.59 (t, 1H, J=7.8 Hz), 7.77 (t, 1H, J=8.4 Hz), 7.88 (d, 1H, J=8.3 Hz), 8.08 (d, 1H, J=8.4 Hz), 8.67 (s, 1H), 9.37 (d, IH, J=2.1 Hz).

METHOD B QUINOLINE-3-CARBOXYLIC ACID (1 (S)-CYCLOHEXYLMETHYL-2(S)- HYDROXY-6-METHYL 4(R)-METHYLCARBAMOYL-HEPTYL4-ENYL)-AMIDE Methylamine was bubbled into a solution of the product from Method A (55 mg, 0.129 mmol) in methanol (2.5 mL). The solution was stirred for 2 hours at room temperature

and the solvent was removed under reduced pressure to provide the title compound (57 mg, 98%) as a pure white solid.

LRMS: 453 (MH+), 421, 283, 173; 1H NMR (300 MHz, CDC13): 5 0.82-1.87 (m, 13H), 1.65 (s, 3H), 2.13 (dd, 1H, J=14.1, 8.7 Hz), 2.38 (d, 1H, J=14.2 Hz), 2.71 (d, 3H, J=4.7 Hz), 2.74 (m, 1H), 3.77 (d, 1H, J=8.7), 4.23 (br, 1H), 4.69 (s, 1H), 4.72 (s, 1H), 5.03 (brs, 1H), 6.60 (q, 1H, J=4.7Hz), 7.24 (d, 1H, J=9.3), 7.54 (t, IH, J=7.1), 7.73 (t, 1H, J=7.1Hz), 7.81 (d, 1H, J=7.1 Hz), 8.04 (d, 1H, J=8.4), 8.61 (d, 1H, J=1.9), 9.33 (s, 1H).

EXAMPLE 2 QUINOXALINE-2-CARBOXYLIC ACID (1(S)-BENZYL-4(R)- BENZYLCARBAMOYLJ-FLUORO-2(S)-HYDROXYJ-METHYL-OCTYL)-AMIDE ALLYLIC ALKYLATION METHOD C: {1(S)-[4(R)-(3-METHYL-BUT-2-ENYL)-5-OXO-TETRAHYDRO-FURAN-2(S )-YL]-2- PHENYL-ETHYL}-CARBAMIC ACID TERT-BUTYL ESTER To a flame dried round bottom flask under a nitrogen atmosphere was added tetrahydrofuran (40 mL) followed by 1,1,1,3,3,3-hexamethyldisilazane (8 mL, 37.8 mmol).

The mixture was cooled to OOC and n-butyl lithium (14.5 mL of a 2.5 M solution in hexanes, 36.0 mmol) was added. The mixture was stirred for 15 minutes, then cooled to -78 °C in dry ice / acetone bath. {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carba mic acid tert-butyl ester (5 g, 16.4 mmol) (prepared by the method of Fray, J. Org Chem., (51) 4828 (1986)) dissolved in tetrahydrofuran (50 mL) was added dropwise via syringe and stirring continued for 30 minutes. A solution of 4-bromo-2-methyl-2-butene (2.07 mL, 18.0 mmol) in 40 mL of THF was added dropwise via syringe. Stirring was continued for 3 hours during which time the temperature rose to 6000. The mixture was quenched by slow addition of saturated, aqueous ammonium chloride (25 mL). Upon warming to room temperature, the solution was diluted with ether (300 mL) and transferred to a separatory funnel. The organic phase was washed with saturated aqueous citric acid (2x100mL), saturated aqueous sodium bicarbonate (NaHCO3)(2xl0OmL), and 100 mL brine. The organic layer was dried over magnesium sulfate (MgS04) and the solvent removed under reduced pressure. Thin layer chromatography in 1:2 hexane/diethyl ether (Et2O) revealed product with an R, of 0.8.

The resulting crude oil was chromatographed on silica gel (2259) eluting with 2:1 hexanes/diethyl ether to provide 4.73 9 (77%) of the title compound. TLC: 1:2 Hexanes/Et2O R,: 0.8. 1H NMR (400 MHz, CDC13): 5 7.27 ppm (5H, m), 5.02 (1H, b), 4.52 (1H, d, J=9.3 Hz), 4.42 (1H, t, J=7.1 Hz), 3.98 (1H, dt, J= 8.5, 7.8 Hz), 2.93 (2H, m), 2.88

(1H, b), 2.68 (1H, m), 2.41 (1H, m), 2.24 (1H, m), 1.92 (1H, m), 1.65 (3H,s), 1.58 (3H,s), 1.37 (9H, s).

METHOD D 5(S)-(1 (S)-AMINO-2-PHENYL-ETHYL)-3(R)-(3-FLUORO-3-METHYL-BUTYL)- DIHYDRO- FURAN-2-ONE To a solution of product from Method C (9.81 9, 26.3 mmol) in dry benzene (300 mL) was added HFpyridine (88 mL). The resulting solution was stirred at ambient temperature for 4 hours, then transferred to a 4 L beaker. To this was added ice, and the pH was slowly adjusted to 8-9 by addition of 2 M aqueous sodium hydroxide (NaOHaq). The mixture was extracted with ethyl acetate (EtOAc) and the organics dried over magnesium sulfate, and then filtered and concentrated. Chromatography on silica gel yielded the title compound (5.68 9, 74%).

METHOD E QUINOXALINE-2-CARBOXYLIC ACID {1(S)-[4(R)d3-FLUORO4-METHYL- BUTYL)-5-OXO-TETRAHYDRO-FURAN-2(S)-YL]-2-PH ENYL-ETHYL}-AMIDE To a solution of quinoxaline carboxylic acid (5.05 9, 29.0 mmol) in methylene chloride (100 mL) was added dimethylaminopyridine (DMAP) (3.55 9, 29.0 mmol) and EDCI (5.55 9, 29.0 mmol). The solution was stirred 10 minutes, then the product from Method D, above, (5.68 9,19.4 mmol) was added in one portion. The solution was stirred for 12 hours, then diluted with diethyl ether and washed with saturated aqueous brine. The organics were dried over magnesium sulfate, and then filtered and concentrated. The crude product was purified by silica gel chromatography to yield the title compound (5.62 9, 64%).

METHOD F QUINOXALINE-2-CARBOXYLIC ACID (1(S)-BENZYL4(R)- BENZYLCARBAMOYL-7-FLUORO-2(S)-HYDROXY-7-METHYL-OCTYL)-AMIDE To a solution of the product from Method E (0.10 9, 0.22 mmol) in dioxane (2 mL) was added glacial acetic acid (0.038 mL, 0.66 mmol) and benzylamine (approx. 1 mL, excess). The resulting solution was warmed to reflux for 1 hour, cooled to ambient temperature and diluted with water. The solution was extracted with ethyl acetate and the combined organics were dried over magnesium sulfate (MgSO4), filtered and concentrated.

Chromatography on silica gel, followed by recrystallization from methylene chloride/hexanes gave the title compound (0.068 9, 56%). m.p. 183-184 °C.

EXAMPLE 3 METHOD F' QUINOXALINE-2-CARBOXYLIC ACID ACID (1-BENZYL-7-FLUORO-2-HYDROXY 4- HYDROXYCARBAMOYL-7-METHYL-OCTYL)-AMIDE Hydroxylamine hydrochloride (1.55g, 22.4 mmol) and KOH (1.519, 26.7 mmol) were combined in anhydrous methanol (20 mL) and stirred for 30 minutes under a dry nitrogen atmosphere, and then filtered. To the resulting filtrate was added the product from Method E (500 mg, 1.17 mmol) and the reaction mixture was stirred for 16 hours at room temperature.

The solvent was removed in vacuo and the residue solvated in EtOAc (50 mL) and transferred to a separated funnel. The organic layer was washed with water and brine and dried (MgS04). After filtration the solvent was removed in vacuo and the remaining residue recrystallized (methylene chloride/Hexanes) to give a pale yellow solid (330 mg, 58%) m.p.

165-166°C EXAMPLE 4 QUINOXALINE-2-CARBOXYLIC ACID (1(S)-BENZYL-4(R)-CARBAMOYL-2(S)- HYDROXY-7-METHYL-OCTYL)-AMIDE METHOD G ALKENE HYDROGENATION {1(S)-[4(R)-(3-METHYL-BUTYL)-5-OXO-TETRAHYDRO-FURAN-2(S)-YL] -2- PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER The product from Method C, from Example 2 above, (3.0 g, 8.04 mmol) was placed in a 250 mL Parr Shaker bottle and dissolved in ethanol (50 mL). Under a nitrogen atmosphere, Palladium (Pd) on activated carbon (0.30 g, 10% Pd content) was added to the solution. The mixture was placed on a Parr Shaker hydrogenator at 50 psi for 5 hours at room temperature. The hydrogenation mixture was diluted with ethyl acetate and then poured through a Celite# pad while washing copiously with ethyl acetate. The solvent of the filtrate was removed in vacuo to yield the title compound, 2.63 g (88%).

'H NMR (400 MHz, CDCl3): 5 7.27 (5H, m), 4.54 (1H, d, J=9.8 Hz), 4.46 (1H, t, J=6.9), 4.0 (1H, dt), 2.89 (2H, d, J=8.1), 2.57 (1H, m), 2.32 (1H, b), 1.89 (1H, m), 1.79 (1H, m), 1.52 (2H, m), 1.37 (9H, s), 1.23 (2H, m), 0.86 (6H, d, J=6.6 Hz).

The product from Method G was converted into the title compound by procedures analogous to those of Methods A and B except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas to yield 0.095 9 (72%) of the title compound.

1H NMR (400 MHz, CDCI3) . 8 9.61(1H, s), 8.32 (1H, d, J=8.9 Hz), 8.16 (2H, m), 7.86 (2H,m), 7.28 (10H, m), 7.19 (1H, m), 5.70 (1H, b), 5.29 (1H, b), 4.27 (1H, m), 8.21 (1H, d, J=4.4 Hz), 3.91 (1H, m), 3.11 (2H, m), 2.46 (1H, m), 1.74 (1H, t, J=6.4 Hz), 1.61 (1H, m), 1.42 (2H, m), 1.17 (1H, m), 1.09 (1H, m), 0.81 (3H, d, J=7.1 Hz), 0.79 (3H, d, J=7.1 Hz). 130 NMR (100 MHz, CDCl3):d 179.11, 163.73, 143.90, 143.76, 143.15, 140.28, 137.96, 131.68, 130.84, 129.84, 129.44, 129.25, 128.58, 126.60, 68.55, 55.90, 43.44, 38.39, 36.90, 36.70, 29.77, 28.03, 22.42 EXAMPLE 5 QUINOXALINE-2-CARBOXYLIC ACID 1(S)-BENZYL-4(R)-CARBAMOYL-2(S)- HYDROXY-7,7-DIMETHYL-OCTYL)-AMIDE METHOD H TRIFLATE ALKYLATION {1-[4-(3,3-DIMETHYL-BUTYL)-5-OXO-TETRAHYDRO-FURAN-2-YL]-2-PH ENYL- ETHYL}-CARBAMIC ACID TERT-BUTYL ESTER To a flame dried round bottom flask under a nitrogen atmosphere was added terahydrofuran (THF) (2 mL) and 1,1,1,3,3,3 hexamethyldisilazane (0.82 mL, 3.88 mmol).

The mixture was cooled to OOC and n-butyl lithium (1.48 mL of a 2.5 M solution in hexanes, 3.72 mmol) was added dropwise via syringe. The mixture was stirred for 15 minutes and then cooled to -780C. {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}carbam ic acid tert-butyl ester (0.52 9, 1.69 mmol prepared by the method of Fray, supra) dissolved in tetrahydrofuran (2 mL) was slowly added to the solution via syringe and the solution was stirred for 1 hour. A solution of the desired triflate, i.e. 3,3-dimethylbutyl triflate (0.92 9, 3.37 <BR> <BR> <BR> mmol)(prepared according to the method of Beard, ., al., J Org Chem., 38, 3673 (1973)) in tetrahydrofuran (2 mL) was added dropwise via syringe and the mixture was stirred for 2 hours at -78°C. The mixture was quenched by addition of saturated aqueous ammonium chloride (NH4CI) (25 mL). Upon warming to room temperature, the mixture was diluted with ethyl acetate (40 mL), transferred to a separatory funnel, and washed with saturated aqueous NH4CI (2x40 mL), saturated NaHOO3 (2x40 mL), and brine (40 mL). The organic layers were dried ( MgS04) and the solvent removed under reduced pressure. The resulting crude oil was chromatographed on silica gel (259) eluting with 100 mL 5:1 hexanes/ethyl acetate followed by 400 mL 4:1 hexanes/ethyl acetate. This provided 0.36 9 (50%) of the title compound.

TLC: (4:1 hexanes/ethyl acetate) Rf: 0.3. 'H NMR (400 MHz, CDCI3) :6 7.25 (m, 7H), 6.92 (t, 1H, J= 7.5 Hz), 6.85 (d, 2H, J= 8.1 Hz), 4.67 (d, 2H, J= 6.0 Hz), 4.49 (t, 1H, J=

9.6 Hz), 4.06 (m, 3H), 2.89 (m, 3H), 2.43 (m, 1H), 2.26 (m, 1H), 2.05 (m, 1H), 1.95 (m, 1H), 1.37 (s, 9H).

The product of Method H was converted to the title compound by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLE 6 QUINOXALINE-2-CARBOXYLIC ACID [1(S)-BENZYL-4(S)-CARBAMOYL-2(S)- HYDROXY -HYDROXY-CYCLOHEXYL)-BUTYL]-AMlDE AND QUINOXALINE-2-CARBOXYLIC ACID M (S)-BENZYL4(R)-CARBAMOYL-2(SL- HYDROXY-4-(1-HYDROXY-CYCLOHEXYL)-BUTYL]-AMIDE METHOD I {1(S)-[4(S)-(1-HYDROXY-CYCLOHEXYL)-5-OXO-TETRAHYDRO-FURAN-2( S)- YL]-2-PHENYL-ETHYL)-CARBAMIC ACID TERT-BUTYL ESTER To a solution of diisopropylamine (0.90 mL, 6.88 mmol) in THF (10 mL) at 0°C was added a solution of n-butyl lithium (2.7 mL, 6.71 mmol, 2.5 M in hexanes). The solution was stirred for 15 minutes, then cooled to - 78 °C. To this was added dropwise a solution of {1(S)-[5-Oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carba mic acid tert-butyl ester (1.0 9, 3.27 mmol prepared as in example 2, method C) in tetrahydrofuran (10 mL) and the reaction was stirred an additional 30 minutes. To this was added the appropriate ketone, e.g., cyclohexanone) (0.37 mL, 3.60 mmol), and the solution was warmed to ambient temperature. The reaction was quenched by addition of saturated aqueous bicarbonated NaHCO3 ) solution and the mixture extracted with diethyl ether. The combined organics were dried over magnesium sulfate (MgSO4), filtered and concentrated. Chromatography on silica gel gave a mixture of separable diastereomers of(tI(S)-[4(S)-(1-hydroxy- cyclohexyl)-5-oxo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}- carbamic acid tert-butyl ester (0.687 g) and {1(S)-[4(R)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2( S)-yl]-2-phenyl- ethyl)-carbamic acid tert-butyl ester (0.269 9) in 67 % overall yield.

The products from Method I were converted to the title compounds by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLE 7 FLUORO-QUINOLINE-3-CARBOXYLIC ACID (1 (S)-BENZYLA(S)-CARBAMOYL- 4-CYCLOHEXYL-2(S)-HYDROXY-BUTYL)-AMIDE AND FLUORO-QUINOLINE-3-CARBOXYLIC ACID (1(S)-BENZYL4(R)-CARBAMOYL- 4-CYCLOHEXYL-2(S)-HYDROXY-BUTYL)-AMIDE METHOD J (1 (S)-14(S)-(1 -HYDROXY-CYCLOH EXYL)-5-OXO-TETRAHYDRO-FURAN-2(S)- YL]-2-PHENYL-ETHYL}-CARBAMlC ACID TERT-BUTYL ESTER To a solution of the title compound from Method I, Example 5, (1.38 9, 3.42 mmol) in benzene (40 mL) was added (methoxycarbonylsulfamoyl)-triethylammonium hydroxide, inner salt (Burgess reagent) (1.30 9, 5.47 mmol) and the solution was warmed to reflux for 2 hours. The reaction was diluted with diethyl ether and washed with saturated aqueous brine.

The organics were dried over magnesium sulfate, filtered and concentrated to give the crude elimination product. This was directly dissolved in 5:1 tetrahydrofuran/methanol (THF/MeOH)(30 mL) and transferred to a Parr flask containing 10% palladium on carbon (Pd/C) (1 9). The mixture was hydrogenated at 35 psi for 1.5 hours, then filtered through a pad of Celite and the filtrate concentrated. Chromatography on silica gel yielded the title compound as a mixture of separable diastereomers (1(S)-[4(S)-(1 -hydroxycyclohexyl)-5- oXo-tetrahydro-furan-2(S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.53 9) and {1(S)-[4(R)-(1-hydroxy-cyclohexyl)-5-oxo-tetrahydro-furan-2( S)-yl]-2-phenyl-ethyl}-carbamic acid tert-butyl ester (0.29 9) in 62 % overall yield.

The products from Method J were converted to the title compounds by procedures analogous to those of Methods A and B, from Example 1, except that quinoline-3-carboxylic acid is replaced with quinoxaline-2-carboxylic acid and methylamine is replaced with ammonia gas.

EXAMPLES 8-312 The compounds from Table 1 were prepared according to the methods described above, substituting where appropriate the correct R2 aldehyde, R3 group (such as allylic halide, alkyl triflate, ketone, etc.), R1 carboxylic acid or R4 and R5 amine where appropriate.

TABLE 1 EXAMPLE NAME M.P. (°C) LRMS 8. Quinoxalin-2-carboxylic acid 455 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl)- amide 9. Quinoxaline-2-carboxylic acid (6-chloro-1-cyclohexylmethyl-2(S)- hydroxy-4(S)-methylcarbamoyl-hept-6- enyl)-amide 10. Quinoline-3-carboxylic acid 155-157 414 (2(S)-hydroxy-1(S)-isobutyl-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 11. Quinoxaline-2-carboxylic acid 69-71 415 1(S)-sec-butyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 12. Quinoline-3-carboxylic acid 452 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-hept-6- enyl)-amide 13. Quinoxaline-2-carboxylic acid 453 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-hept-6- enyl)-amide 14. N-1(S)-Cyclohexylmethyl-2(S)- 115-119 hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-5-phenyl- nicotinamide 15. Quinoline-3-carboxylic acid 1(S)- 162-163 benzyl-2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl)-amide 16. Quinoxaline-2-carboxylic acid 467 1(S)-cyclohexylmethyl-4(R)- dimethylcarbamoyl-2(S)-hydroxy-6- methyl-hept-6-enyl)-amide 17. Quinoline-3-carboxylic acid 171-175 453. 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- 436 methyl-4(S)-methylcarbamoyl-heptyl)- amide 18. Quinoxaline-2-carboxylic acid 455, 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- 437 methyl-4(S)-methylcarbamoyl-heptyl)- amide 19. Isoquinoline-4-carboxylic acid 180-182 454 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(S)-methylcarbamoyl-heptyl)- amide 20. Quinoline-3-carboxylic acid 186-188 440, (4(R)-carbamoyl-1(S)-cyclohexylmethyl- 478, 2(S)-hydroxy-6-methyl-heptyl)-amide 423 TABLE 1 EXAMPLE NAME M.P. (0C) LRMS 21. Quinoline-3-carboxylic acid (5- 170.5-172.5 494 cyclohexyl-1 (S)-cyclohexylmethyl-2(S)- hydroxy4(R)-methylcarbamoyl-pentyl)- amide 22. Quinoline-3-carboxylic acid 1(S)- 454 cyclohexylmethyl-2(S)-hydroxy-6- methyl4(R)-methylcarbamoyl-heptyl)- amide 23. Quinoline-3-carboxylic acid 200-201.5 454 1(S)-cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(S)-methylcarbamoyl-heptyl)- amide 24. Quinoline-3-carboxylic acid 199-200.5 488 1(S)-cyclohexylmethyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-5-phenyl- pentyl)-amide 25. Quinoxaline-2carboxylic acid 109-110.5 489 1 (S)-cyclohexylmethyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-5-phenyl- penty 1)-amide 26. Quinoline-3-carboxylic acid 142-144 490, 1 (S)-benzyl4(R)-butylcarbamoyl-2(S)- 417 hydroxy-6-methyl-heptyl)-amide 27. Quinoline-3-carboxylic acid 148-150 488, I (S)-benzyl4(R)-cyclobutylcarbamoyl- 417 2(S)-hydroxy-6-methyl-heptyl)-amide 28. Quinoline-3-carboxylic acid 158-162 524, 1 (S)-benzyl4(R)-benzylcarbamoyl- 417 2(S)-hydroxy-6-methyl-heptyl)-amide 29. Quinoline-3-carboxylic acid 174-179 474 1 (S)-benzyl4(R)- cyclopropylcarbamoyl-2(S)-hyd roxy-6- methyl-heptyl)-amide 30. QuinoIine-3carboxylic acid 190-192.5 448 1 (S)-benzyl-2(S)-hyd roxy-6-methyl- 4(S)-methylcarbamoyl-heptyl)-amide 31. Quinoline-3-carboxylic acid 175-176 462 1 (S)-benzyl4(R)-ethylcarbamoyl-2(S)- hydroxy -6-methyl-heptyl)-amide 32. Quinoline-3-carboxylic acid 476 I (S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-propylcarbamoyl-heptyl)-amide 33. Quinoline-3-carboxylic acid 158-162 478 [1-benzyl-2(S)-hydroxy-4(R)-(2- hydroxy-ethylcarbamoyl)-6-methyl- heptyl]-amide 34. Cinnoline-4(R)-carboxylic acid 185-186.5 449 1 (S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 35. Isoquinoline-4-carboxylic acid 200-201 448 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 36. Quinoxaline-2-carboxylic acid 166-167 449 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 37. N-1(S)-Benzyl-2(S)-hydroxy-6-methyl- 184.5-185.5 478 4(R)-methylcarbamoyl-heptyl)-5- bromo-nicotinamide 38. Quinoline-3-carboxylic acid 454 1(R)-cyclohexylmethyl-2(R)-hydroxy-6- methyl-4(S)-methylcarbamoyl-heptyl)- amide 39. Quinoxaline-2-carboxylic acid 196-197 554 [1(S)-(4-benzyloxy-benzyl)-2(S)- hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide, 40. Quinoline-3-carboxylic acid 178-179 555 [1(S)-(4-benzyloxy-benzyl)-2(S)- hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide 41. Isoquinoline-1-carboxylic acid 178-179 448 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 42. Quinoline-4-carboxylic acid 189-192 448 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 43. Quinoline-6-carboxylic acid 165-167 448 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 44. Quinoline-3-carboxylic acid 220.5-222.5 464 [2(S)-hydroxy-1(S)-(4-hydroxy-benzyl)- 6-methyl-4(R)-methylcarbamoyl- heptyl]-amide 45. Quinoline-2-carboxylic acid 160-161.5 449 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 46. Naphthalene-2-carboxylic acid 218-220 447 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 47. Quinoline-3-carboxylic acid 172-174 486 1(S)-benzyl-5-cyclohex-1-enyl-2(S)- hydroxy-4(R)-methylcarbamoyl-pentyl)- amide 48. Quinoline-3-carboxylic acid 153-154 504 [1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-(3-methyl-butylcarbamoyl)- heptyl]-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 49. Quinoxaline-2-carboxylic acid 157-163 449 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(S)-methylcarbamoyl-heptyl)-amide 50. Trifluoro-methanesulfonic acid 168-170 596 4-{3(S)-hydroxy-7-methyl-5(R)- methylcarbamoyl-2(S)-[(quinoline-3- carbonyl)-amino]-octyl}- phenyl ester 51. Trifluoro-methanesulfonic acid 597 4-{3(S)-hydroxy-7-methyl-5(R)- methylcarbamoyl-2(S)-[(quinoxaline- 2-carbonyl)-amino]-octyl}-phenyl ester 52. Quinoline-3-carboxylic acid 185-187 488 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide 53. Quinoxaline-2-carboxylic acid 132-134 489, 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy- 471 4(R)-methylcarbamoyl-pentyl)-amide 54. Iosquinoline-3-carboxylic acid 150.5-151.5 488 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide 55. N-1(S)-Benzyl-5-cyclohexyl-2(S)- 199-200.5 518 hydroxy-4(R)-methylcarbamoyl-pentyl)- 5-bromo-nicotinamide 56. Quinoline-3-carboxylic acid 1(S)- 472 benzyl-2(S)-hydroxy-6-methyl-4(R)- prop-2-ynylcarbamoyl-heptyl)-amide 57. Quinoline-3-carboxylic acid 456, 1(S)-cyclohexylmethyl-2(S)-hydroxy- 438, 4(R)-hydroxycarbamoyl-6-methyl- 423 heptyl)-amide 58. Quinoline-3-carboxylic acid 2(S)- 176-177 478 hydroxy-1(S)-(4-methoxy-benzyl)-6- methyl-4(R)-methylcarbamoyl-heptyl]- amide 59. Isoquinoline-3-carboxylic acid (5- 205-207 494 cyclohexyl-1(S)-cyclohexylmethyl-2(S)- hydroxy-4(R)-methylcarbamoyl-pentyl)- amide, 60. 5-Bromo-N-(5-cyclohexyl-1(S)- 173.5-175 444 cyclohexylmethyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-nicotinamide 61. Quinoxaline-2-carboxylic acid 479 [2(S)-hydroxy-1(S)-(4-methoxy- benzyl)-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide 62. isoquinoline-4-carboxylic acid 220.5-224 494 (5-cyclohexyl-1(S)-cyclohexylmethyl- 2(S)-hydroxy-4(R)-methylcarbamoyl- pentyl)-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 63. Quinoline-2-carboxylic acid 120-122 488 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide 64. Isoquinoline-4-carboxylic acid 177-180 488 1(S)-benzyl-5-cyclohexyl-2(S)-hydroxy- 4(R)-methylcarbamoyl-pentyl)-amide, 65. Quinoxaline-2-carboxylic acid 170-172 465 [2(S)-hydroxy-1(S)-(4-hydroxy-benzyl)- 6-methyl-4(R)-methylcarbamoyl- heptyl]-amide, 66. Quinoxaline-2-carboxylic acid 496 (5-cyclohexyl-1(S)-cyclohexylmethyl- 2(S)-hydroxy-4(R)-methylcarbamoyl- pentyl)-amide 67. Quinoline-3-carboxylic acid 212.5-213.5 482 [1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl]- amide 68. Quinoxaline-2-carboxylic acid 483 [1(S)-(4-chloro-benzyl)-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl]- amide 69. Quinoline-3-carboxylic acid 173.5-175 468, 1(S)-cyclohexylmethyl-2(S)-hydroxy-7- 450 methyl-4(R)-methylcarbamoyl-octyl)- amide 70. Quinoxaline-2-carboxylic acid 78-80 470 1(S)-cyclohexylmethyl-2(S)-hydroxy-7- methyl-4(R)-methylcarbamoyl-octyl)- amide 71. Quinoline-3-carboxylic acid 198-201 522 [1(S)-(4-chloro-benzyl)-5-cyclohexyl- 2(S)-hydroxy-4(R)-methylcarbamoyl- pentyl]-amide 72. Quinoxaline-2-carboxylic acid 523 [1(S)-(4-chloro-benzyl)-5-cyclohexyl- 2(S)-hydroxy-4(R)-methylcarbamoyl- pentyl]-amide 73. Quinoline-2-carboxylic acid 522 [1(S)-(4-chloro-benzyl)-5-cyclohexyl- 2(S)-hydroxy-4(R)-methylcarbamoyl- pentyl]-amide 74. Benzofuran-2-carboxylic acid 181-183 437 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 75. N-1(S)-Benzyl-2(S)-hydroxy-6-methyl- 195-196 466, 4(R)-methylcarbamoyl-heptyl)-5,6- 432 dichloro-nicotinamide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 76. Quinoline-3-carboxylic acid 188-190 462 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 77. N-1(S)-Benzyl-2(S)-hydroxy-7-methyl- 188-189 490 4(R)-methylcarbamoyl-octyl)-5-bromo- nicotinamide 78. 5,6,7,8-Tetrahydro-quinoline-3- 142.5-144.5 452 carboxylic acid 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 79. Quinoxaline-2-carboxylic acid 147-149 463 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 80. Quinoline-2-carboxylic acid 156-158 462 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide, 81. isoquinoline-4-carboxylic acid 199-202 462 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 82. Quinoxaline-2-carboxylic acid 517, [1(S)-(3,4-dichloro-benzyl)-2(S)- 483 hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide 83. Benzo[b]thiophene-2-carboxylic acid 179-181 453 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 84. 2-Methyl-quinoline-3-carboxylic acid 225-226.5 462 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 85. 6,7-Dimethoxy-quinoline-3-carboxylic 211-214 508 acid 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 86. 6,7-Difluoro-quinoline-3-carboxylic acid 187-189 484, 1(S)-benzyl-2(S)-hydroxy-6-methyl- 466 4(R)-methylcarbamoyl-heptyl)-amide 87. 1H-Benzoimidazole-2-carboxylic acid 136-140 437 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 88. 5-Methyl-pyrazine-2-carboxylic acid 171.5-172.5 413 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 89. Quinoline-3-carboxylic acid 184-186 466 [1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl]- amide 90. Quinoxaline-2-carboxylic acid 153-156 467 [1(S)-(4-fluoro-benzyl)-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl]- amide TABLE 1 EXAMPLE NAME M.P. (0C) LRMS 91. 5-Chloro-1 H-indole-2-carboxylic acid 245-247 470 I (S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 92. Quinoxaline-2-carboxylic acid 194-194.5 449, 1 (S)-benzyl-4(R)-carbamoyl-2(S)- 432 hydroxy-7-methyl-octyl)-amide 93. 2-Methoxy-quinoline-3-carboxylic acid 175-181 478 1 (S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide, 94. 5,6-Dichloro-1 H-benzoimidazole-2- 114-117 505 carboxylic acid 1(S)-benzyl-2(S)- hydroxy-6-methyl4(R)- methylcarbamoyl-heptyl)-amide 95. Benzothiazole-2-carboxylic acid 86-89 454 1 (S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 96. 7,8-Difluoro-quinoline-3-carboxylic acid 179-182 484 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 97. 6,7,8-Trifluoro-quinoline-3-carboxylic 156-161 502, acid 484 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 98. 5,8-Dimethylquinoline-3-carboxylic 197-199 476 acid 1(S)-benzyl-2(S)-hydroxy-6- methyl4(R)-methylcarbamoyl-heptyl)- amide 99. Quinoxaline-2-carboxylic acid 103-106 505 1 (S)-benzyl4(R)-butylcarbamoyl-2(S)- hydroxy-7-methyl-octyl)-amide ~ 100. Quinoline-3-carboxylic acid 516 [i(S)-(3,4-dichloro-benzyl)-2(S)- hydroxy-6-methyl4(R)- methylcarbamoyl-heptyli-amide 101. 5,6,7,8-Tetrahydro-quinoline-3- 169.5-172.5 466 carboxylic acid 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 102. Quinoline-3-carboxylic acid 176-178 474 1(S)-benzyl-5-cyclopentyl-2(S)- hydroxy-4(R)-methylcarbamoyl-pentyl)- amide 103. Quinoxaline-2-carboxylic acid 120-122 475 1 (S)-benzyl-5-cyclopentyl-2(S)- hydroxy-4(R)-methylcarbamoyl-pentyl)- amide 104. N-1 (S)-Benzyl-5-cyclopentyl-2(S)- 194-198 504 hydroxy-4(R)-methylcarbamoyl-pentyl)- 5-bromo-nicotinamide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 105. 5,6,7,8-Tetrahydro-quinoline-3- 143-146 478 carboxylic acid 1(S)-benzyl-5- cyclopentyl-2(S)-hydroxy-4(R)- methylcarbamoyl-pentyl)-amide, 106. Quinoxaline-2-carboxylic acid 217-219 461, 1(S)-benzyl-4(R)-carbamoyl-5- 444 cyclopentyl-2(S)-hydroxy-pentyl)-amide 107. 6,7-Dihydro-5H-[1]pyrindine-3- 154.5-156 452, carboxylic acid 349 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 108. Quinoxaline-2-carboxylic acid 95-98 491, [1(S)-(4,4-difluoro-cyclohexylmethyl)- 473 2(S)-hydroxy-6-methyl-4(R)- methylcarbamoyl-heptyl]-amide 109. Quinoxaline-2-carboxylic acid 95-98 506, [1(S)-(4,4-difluoro-cyclohexylmethyl)- 488 2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl]-amide 110. Quinoxaline-2-carboxylic acid 129-133 478 1(S)-benzyl-4(R)-ethylcarbamoyl-2(S)- hydroxy-7-methyl-octyl)-amide 111. Quinoxaline-2-carboxylic acid 125-130 492 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-propylcarbamoyl-octyl)-amide 112. Quinoxaline-2-carboxylic acid 168-169 490, 1(S)-benzyl-4(R)- 472 cyclopropylcarbamoyl-2(S)-hydroxy-7- methyl-octyl)-amide 113. Quinoxaline-2-carboxylic acid 148-150 504, 1(S)-benzyl-4(R)-cyclobutylcarbamoyl- 486 2(S)-hydroxy-7-methyl-octyl)-amide 114. Quinoxaline-2-carboxylic acid 151-154 530 [1(S)-(4-difluoromethoxy-benzyl)-2(S)- hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl]-amide 115. 4-{3(S)-Hydroxy-7-methyl-5(R)- 87-95 508 methylcarbamoyl-2(S)-[(quinoxaline- 2-carbonyl)-amino]-octyl}-benzoic acid methyl ester 116. Quinoxaline-2-carboxylic acid 1(S)- 379 benzyl-4-carbamoyl-2(S)-hydroxy- butyl)-amide 117. 6,7,8-Trifluoro-quinoline-3-carboxylic 206-207 516, acid 498 1(S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide TABLE 1 EXAMPLE NAME M.P. (°C) LRMS 118. 6,7,8-Trifluoro-quinoline-3-carboxylic 205-206 502, acid 485 1(S)-benzyl-4(R)-carbamoyl-2(S)- hydroxy-7-methyl-octyl)-amide 119. 6,8-Difluoro-quinoline-3-carboxylic acid 198-200 498 I (S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-octyl)-amide 120. 6,8-Difluoro-quinoline-3-carboxylic acid 188-190 484, I (S)-benzyl4(R)-carbamoyl-2(S)- 467 hydroxy-7-methyl-octyl)-amide 121. Quinoxaline-2-carboxylic acid 102-104 517, 1(S)-benzyl-4(R)-butylcarbamoyl-5- 499 cyclopentyl-2(S)-hydroxy-pentyl)-amide 122. 6-Methyl-pyridine-2-carboxyiic acid 74-76 1(S)-benzyl-2(S)-hydroxy-6-methyl- 4(R)-methylcarbamoyl-heptyl)-amide 123. Quinoxaline-2-carboxylic acid 145.5-146.5 477 1 (S)-benzyl-2(S)-hydroxy-8-methyl- 4(R)-methylcarbamoyl-nonyl)-amide 124. Quinoxaline-2-carboxylic acid 163-165 463 1 (S)-benzyl4(R)-carbamoyl-2(S)- hydroxy-8-methyl-nonyl)-amide 125. Quinoxaline-2-carboxylic acid 123-125 539, 1(S)-biphenyl-4-ylmethyl-2(S)-hydroxy- 521, 7-methyl-4(R)-methylcarbamoyl-octyl)- 508 amide 126. Quinoxaline-2-carboxylic acid 168-170 447, 1(S)-benzyl-4(R)-carbamoyl-2(S)- 430 hydroxy-7-methyl-oct-6-enyl)-amide 127. Quinoxaline-2-carboxylic acid 121-123 (2(S)-hydroxy-6-methyl4(R)- methylcarbamoyl-1(S)-naphthalen-2- ylmethyl-heptyl)-amide 128. Quinoxaline-2carboxylic acid 77-79 463, 1 (S)-benzyl4(R)-carbamoyl-2(S)- 446 hydroxy-7,7-dimethyl-octyl)-amide 129. Quinoxaline-2-carboxylic acid 195-199 477, I (S)-benzyl-2(S)-hydroxy-7,7-dimethyl- 459 4(R)-methylcarbamoyl-octyl)-amide 130. Quinoxaline-2-carboxylic acid 168-172 469, 1(S)-benzyl-4(R)-carbamoyl-2(S)- 452 hydroxy-5-phenyl-pentyl)-amide 131. Quinoxaline-2-carboxylic acid 205-206 508 1(S)-biphenyl-4-ylmethyl-4(R)- carbamoyl-2(S)-hydroxy-7-methyl- octylkamide 132. Quinoxaline-2-carboxylic acid 170-172 525, [1(S)-benzyl-5-(4,4-difluoro- 507 cyclohexyl)-2(S)-hydroxy4(R)- methylcarbamoyl-pentyl]-amide TABLE i EXAMPLE NAME M.P. (°C) LRMS 133. Quinoxaline-2carboxylic acid 174-176 511, [1 (S)-benzyl4(R)-carbamoyl-5-(4,4- 493 difluoro-cyclohexyl)-2(S)-hydroxy- pentyl]-amide 134. Quinoxaline-2carboxylic acid 158.5-159.5 481, [1 (S)-(3-fluoro-benzyl)-2(S)-hydroxy-7- 463 methyl-4(R)-methylcarbamoyl-octyl]- amide 135. Quinoxaline-2-carboxylic acid 191-191.5 467, [4(R)-carbamoyl-1 (S)-(3-fluoro-benzyl)- 449 2(S)-hydroxy-7-methyl-octyl]-amide 136. Quinoxaline-2-carboxylic acid 65-68 461. 1(S)-benzyl-2(S)-hydroxy-7-methyl- 443 4(R)-methylcarbamoyl-oct-6-enyl)- amide 137. 6,7,8-Trifluoro-quinoline-3-carboxylic 158-161 541, acid I (S)-benzyl-2(S)-hydroxy-7(S)- 523 methyl-4(R)-methylcarbamoyl-nonyl)- amide 138. Quinoxaline-2-carboxylic acid 185-187 446 I (S)-benzyl4(R)-carbamoyl-2(S)- hydroxy-7(S)-methyl-nonyl)-amide 139. Quinoxaline-2-carboxylic acid 148-150 482, 1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- 463 methyl-4(R)-methylcarbamoyl-octyl)- amide 140. Quinoxaline-2-carboxylic acid 184-186 467, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 449 2(S)-hydroxy-7-methyl-octyl)-amide 141. Quinoxaline-2-carboxylic acid 137-139.5 478 1 (S)-benzyl-2(S)-hydroxy-7-methyl- 4(R)-methylcarbamoyl-nonyl)- amide 142. Quinoxaline-2-carboxylic acid 68-70 1(S)-benzyl-4(R)-dimethylcarbamoyl- 2(S)-hydroxy-7-methyl-octyl)-amide 143. 7,8-Difluoro-quinoline-3-carboxylic acid 175 518, 1 (S)-benzyl-2(S)-hy droxy4(R)- (Dec.) 500 methylcarbamoyl-5-phenyl-pentyl)- amide 144. 7,8-DiRuoro-quinoline-3-carboxylic acid 198-201 498, 1 (S)-benzyl-2(S)-hydroxy-7-methyl- 480 4(R)-methylcarbamoyl-octyl)-amide 145. 8-Fluoro-quinoline-3carboxylic acid 179-183 480, I (S)-benzyl-2(S)-hydroxy-7-methyl- 462 4(R)-methylcarbamoyl-octyl)-amide 146. Quinoxaline-2-carboxylic acid 130-132 462, I (S)-benzyl-2(S)-hydroxy4(R)- 448 methylcarbamoyl-non-6-enyl)-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 147. Quinoxaline-2-carboxylic acid 154-155 448, 1(S)-benzyl-4(R)-carbamoyl-2(S)- 430 hydroxy-non-6-enyl)-amide 148. 7,8-Difluoro-quinoline-3-carboxylic acid 188-190 485, 1(S)-benzyl-4(R)-carbamoyl-2(S)- 467 hydroxy-7-methyl-octyl)-amide 149. 8-Fluoro-quinoline-3-carboxylic acid 192-196 466, 1(S)-benzyl-4(R)-carbamoyl-2(S)- 449 hydroxy-7-methyl-octyl)-amide 150. Quinoxaline-2-carboxylic acid 188.5-189.5 450 1(S)-benzyl-4(R)-carbamoyl-2(S)- hydroxy-nonyl)-amide 151. 2(S)-{2(S)-hydroxy-4-phenyl-3(S)- 178-180 [(quinoxaline-2-carbonyl)-amino]- butyl}-N1,N4-dimethyl-succinamide 152. Quinoxaline-2-carboxylic acid 105-108 496 1(S)-benzyl-4(R)-ethylcarbamoyl-7- fluoro-2(S)-hydroxy-7-methyl-octyl)- amide 153. Quinoxaline-2-carboxylic acid 110-112 523, 1(S)-benzyl-4(R)-butylcarbamoyl-7- 505 fluoro-2(S)-hydroxy-7-methyl-octyl)- amide 154. Quinoxaline-2-carboxylic acid 145-147 499 [7-fluoro-1(S)-(4-fluoro-benzyl)-2(S)- hydroxy-7-methyl-4(R)- methylcarbamoyl-octyl]-amide 155. Quinoxaline-2-carboxylic acid 206-207 536, [4(R)-carbamoyl-1(S)-(3,4-dichloro- 518 benzyl)-7-fluoro-2(S)-hydroxy-7- methyl-octyl]-amide 156. 7,8-Difluoro-quinoline-3-carboxylic acid 187-189 571 [4(R)-carbamoyl-1(S)-(3,4-dichloro- benzyl)-7-fluoro-2(S)-hydroxy-7- methyl-octyl]-amide 157. Quinoxaline-2-carboxylic acid 223-225 478 (4(R)-carbamoyl-2(S)-hydroxy-7- methyl-1(S)-phenethyl-octyl)-amide, 158. 7,8-Difluoro-quinoline-3-carboxylic acid 208-210 463, [4(R)-carbamoyl-7-fluoro-1(S)-(4- 445 fluoro-benzyl)-2(S)-hydroxy-7-methyl- octyl]-amide 159. Quinoxaline-2-carboxylic acid 520 [4(R)-carbamoyl-7-fluoro-1(S)-(4- fluoro-benzyl)-2(S)-hydroxy-7-methyl- octyl]-amide 160. Quinoxaline-2-carboxylic acid 551 [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-4(R)-(4-methyl-piperazine-1- carbonyl)-octyl]-amide.

TABLE 1 EXAMPLE NAME M.P. (0C) LRMS 161. Quinoxaline-2-carboxylic acid 212-214 477, [1 (S)-benzyl4(R)-carbamoyl-2(S)- 459 hydroxy-5-(tetrahydro-pyran-4(R)-yl)- pentyl]-amide 162. Quinoxaline-2-carboxylic acid 536 [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-4(R)-(piperidine-1-carbonyl)- octyl]-amide 163. Quinoxaline-2-carboxylic acid 537 [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-4(R)-(morpholine-4-carbonyl)- octylj-amide, 164. Quinoxaline-2-carboxylic acid 90-100 481, [1(S)-benzyl-3-(2-carbamoyl-indan-2- 464 yl)-2(S)-hydroxy-propyl]-amide 165. Quinoxaline-2-carboxylic acid 212-216 1 (S)-benzyl-2(S)-hydroxy4(R)- (Dec.) methylcarbamoyi-7-phenyl-hept-6- enyl)-amide 166. Quinoline-2-carboxylic acid 163.5-165 466, 1 (S)-benzyl4(R)-carbamoyl-7-fluoro- 449 2(S)-hydroxy-7-methyl-octyi)-amide 167. 6.7-Dihydro-5H-(I]pyrindine-3- 175-178 456 carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 2(S)-hydroxy-7-methyl-octyl)-amide 168. Quinoxaline-2-carboxylic acid (1(S)- 222-223 461. benzyl-4-carbamoyl-4(S)-cyclohexyl- 444 2(S)-hydroxy-butyl)-amide; 169. Quinoxaline-2-carboxylic acid (1(S)- 178-180 461, benzyl-4-carbamoyl-4(S)-cyclohexyl- 444 2(S)-hydroxy-butyl)-amide 170. Quinoxaline-2-carboxylic acid (1(S)- 229-232 447 benzyl-4-carbamoyl-4(S)-cyclohexyl- 2(S)-hydroxy-butyl)-amide 171. Quinoxaline-2-carboxylic acid (1(S)- 126-128 447 benzyl4-carbamoyl4(S)-cyclopentyl- 2(S)-hydroxy-butyl)-amide; 172. Quinoline-3-carboxylic acid 200-202 466. 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 449 2(S)-hydroxy-7-methyl-octyl)-amide 173. N-1 (S)-Benzyl4(R)-carbamoyl-7- 181-I 83 476 fluoro-2(S)-hydroxy-7-methyl-octyl)-5- bromo-nicotinamide 174. Quinoxaline-2-carboxylic acid 184-187 466, [4(R)-carbamoyl-l-(2(S)-fiuoro-benzyl)- 448 2(S)-hydroxy-7-methyl-octyl]-amide 175. Quinoxaline-2-carboxylic acid 213-215 466 [4(R)-carbamoyl-1 (S)-(2-fluoro-benzyl)- 2(S)-hydroxy-7-methyl-octyl]-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 176. Quinoxaline-2-carboxylic acid [1(S)- 502 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (4-isopropyl-cyclohexyl)-butyl]-amide; 177. Quinoxaline-2-carboxylic acid 454, (4(R)-carbamoyl-2(S)-hydroxy-7- 436 methyl-1(S)-thiophen-2-ylmethyl-octyl)- amide 178. Quinoxaline-2-carboxylic acid 195-196 456 (4(R)-carbamoyl-2(S)-hydroxy-7- methyl-1(S)-thiazol-4-ylmethyl-octyl)- amide 179. Quinoxaline-2-carboxylic acid [1(S)- 188-190 516 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (3,3,5,5-tetramethyl-cyclohexyl)-butyl]- amide 180. Quinoxaline-2-carboxylic acid (1(S)- 495 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- indan-2-yl-butyl)-amide; 181. Quinoxaline-2-carboxylic acid (1(S)- 216-217 474, benzyl-4(S)-carbamoyl-4-cycloheptyl- 457 2(S)-hydroxy-butyl)-amide; 182. Quinoxaline-2-carboxylic acid (1(S)- 477 benzyl-4(S)-carbamoyl-2(S)-hydroxy-5- propyl-octyl)-amide; 183. Quinoxaline-2-carboxylic acid (1(S)- benzyl-4(S)-carbamoyl-2(S)-hydroxy-5- propyl-oct-5-enyl)-amide; 184. Quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S),7- dihydroxy-7-methyl-octyl)-amide 185. Quinoxaline-2-carboxylic acid 467, 1(S)-benzyl-7-chloro-2(S)-hydroxy- 449 4(R)-methylcarbamoyl-hept-6-enyl)- amide 186. Quinoxaline-2-carboxylic acid 467, 1(S)-benzyl-7-chloro-2(S)-hydroxy- 449 4(R)-methylcarbamoyl-hept-6-enyl)- amide 187. Quinoxaline-2-carboxylic acid 160-162 467, 1(S)-benzyl-6-chloro-2(S)-hydroxy- 449 4(S)-methylcarbamoyl-hept-6-enyl)- amide 188. Quinoxaline-2-carboxylic acid 203-204.5 1(S)-benzyl-4(R)-carbamoyl-6-chloro- 2(S)-hydroxy-hept-6-enyl)-amide 189. Quinoxaline-2-carboxylic acid 171-174 447, 1(S)-benzyl-4(S)-carbamoyl-6- 429 cyclopropyl-2(S)-hydroxy-hexyl)-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 190. Quinoxaline-2-carboxylic acid 146-148 461, 1(S)-benzyl-6-cyclopropyl-2(S)- 443 hydroxy-4(R)-methylcarbamoyl-hexyl)- amide 191. Quinoxaline-2-carboxylic acid [1(S)- 218-220 475, benzyl-4(R)-carbamoyl-2(S)-hydroxy- 457 4(S)-(4-methyl-cyclohexyl)-butyl]- amide; 192. Quinoxaline-2-carboxylic acid (1(S)- 190-191 495, benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- 477 indan-2-yl-butyl)-amide; 193. Quinoxaline-2-carboxylic acid 184-187 553, [1(S)-benzyl-4(R)-carbamoyl-2(S)- 536 hydroxy-5-(4-trifluoromethoxy-phenyl)- pentyl]-amide 194. Quinoxaline-2-carboxylic acid 164-166 487, [1(S)-benzyl-4(R)-carbamoyl-5-(4- 470 fluoro-phenyl)-2(S)-hydroxy-pentyl]- amide 195. Quinoxaline-2-carboxylic acid 165-166 436 1(S)-benzyl-4(R)-carbamoyl-7-chloro- 2(S)-hydroxy-hept-6-enyl)-amide 196. Quinoxaline-2-carboxylic acid 158-160 436 1(S)-benzyl-4(R)-carbamoyl-7-chloro- 2(S)-hydroxy-hept-6-enyl)-amide 197. 3-Hydroxy-quinoxaline-2-carboxylic 185-189 483, acid 1(S)-benzyl-4(R)-carbamoyl-7- 465 fluoro-2(S)-hydroxy-7-methyl-octyl)- amide 198. Quinoxaline-2-carboxylic acid 183-184 1(S)-benzyl-4(R)-benzylcarbamoyl-7- fluoro-2(S)-hydroxy-7-methyl-octyl)- amide 199. Quinoxaline-2-carboxylic acid 188-191 {1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-4(R)-[(pyridin-3-ylmethyl)- carbamoyl]-octyl}-amide 200. Quinoxaline-2-carboxylic acid 571, 1(S)-benzyl-8,8-trifluoro-2(S)-hydroxy- 553 4(R)-methylcarbamoyl-7- trifluoromethyl-octyl)-amide 201. Quinoxaline-2-carboxylic acid 187-193 553 1(S)-benzyl-4(R)-carbamoyl-8,8- trifluoro-2(S)-hydroxy-7-trifluoromethyl- octyl)-amide 202. Quinoxaline-2-carboxylic acid 170-173 502 [2(S)-hydroxy-7-methyl-4(R)- methylcarbamoyl-1(S)-(4- methylcarbamoyl-benzyl)-octyl]-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 203. Quinoxaline-2-carboxylic acid (1(S)- 215-218 448, benzyl-4(S)-carbamoyl-5-ethyl-2(S)- 431 hydroxy-heptyl)-amide; 204. Quinoxaline-2-carboxylic acid [1(S)- 151-154 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (tetrahydro-pyran-4-yl)-butyl]-amide; 205. Quinoxaline-2-carboxylic acid 155-156 572 [1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-4(R)-(2-pyridin-2-yl- ethylcarbamoyl)-octyl]-amide 206. Quinoxaline-2-carboxylic acid 162-164 617 [1(S)-benzyl-4(R)-(3,4-dimethoxy- benzylcarbamoyl)-7-fluoro-2(S)- hydroxy-7-methyl-octyl]-amide 207. Quinoxaline-2-carboxylic acid 1(S)- 420 benzyl-4(R)-carbamoyl-2(S)-hydroxy- 6-methoxy-hexyl)-amide 208. Quinoxaline-2-carboxylic acid 172-175 450 1(S)-benzyl-4(R)-carbamoyl-7-chloro- 2(S)-hydroxy-oct-6-enyl)-amide 209. Quinoxaline-2-carboxylic acid 108-111 463 1(S)-benzyl-7-chloro-2(S)-hydroxy- 4(R)-methylcarbamoyl-oct-6-enyl)- amide 210. Quinoxaline-2-carboxylic acid [1(S)- 221-222 489, benzyl-4(R)-carbamoyl-4-(3,5- 471 dimethyl-cyclohexyl)-2(S)-hydroxy- butyl]-amide; 211. Quinoxaline-2-carboxylic acid {1(S)- 138-140 557, benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 540 4(R)-[(pyridin-2-ylmethyl)-carbamoyl]- octyl}-amide 212. Quinoxaline-2-carboxylic acid {1(S)- 138-140 587, benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2- 569 (4-hydroxy-phenyl)-ethylcarbamoyl]-7- methyl-octyl}-amide 213. Quinoxaline-2-carboxylic acid {1(S)- 174-175 563, benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 545 4(R)-[(thiophen-2-ylmethyl)- carbamoyl]-octyl}-amide 214. Quinoxaline-2-carboxylic acid 194.5-196.5 482 1(S)-benzyl-4(R)-carbamoyl-2(S)- hydroxy-6-phenoxy-hexyl)-amide 215. Quinoxaline-2-carboxylic acid 113-118 448 1(S)-benzyl-4(R)-carbamoyl-2(S)- (Mix) hydroxy-6-isopropoxy-hexyl)-amide 216. Quinoxaline-2-carboxylic acid {1(S)- 207-210 650 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-[2-(4-sulfamoyl-phenyl)- ethylcarbamoyl]-octyl}-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 217. Quinoxaline-2-carboxylic acid {1(S)- 100-104 558 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-[(pyridin-4-ylmethyl)-carbamoyl]- octyl}-amide 218. Quinoxaline-2-carboxylic acid [1(S)- 78-79 555, benzyl-4(R)-(2-ethylsulfanyl- 537 ethylcarbamoyl)-7-fluoro-2(S)-hydroxy- 7-methyl-octyl]-amide 219. Quinoxaline-2-carboxylic acid [1(S)- 48-50 507 benzyl-7-fluoro-2(S)-hydroxy-4(R)-(2- methoxy-ethylcarbamoyl)-7-methyl- octyl]-amide 220. Quinoxaline-2-carboxylic acid [1(S)- 154-155 572 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-(2-pyridin-3-yl-ethylcarbamoyl)- octyl]-amide 221. Quinoxaline-2-carboxylic acid [1(S)- 78-80 572 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-(2-pyridin-4-yl-ethylcarbamoyl)- octyl]-amide 222. Quinoxaline-6-carboxylic acid 190-192 467 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 2(S)-hydroxy-7-methyl-octyl)-amide 223. Quinoxaline-2-carboxylic acid 184-189 479, 1(S)-benzyl-6-tert-butoxy-4(R)- 461 carbamoyl-2(S)-hydroxy-hexyl)-amide 224. Quinoxaline-2-carboxylic acid {1(S)- 100-105 574 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-[2-1-methyl-1H-pyrrol-2-yl)- ethylcarbamoyl]-octyl}-amide 225. Quinoxaline-2-carboxylic acid [1(S)- 140-150 511, benzyl-4(S)-carbamoyl-4-(1,1-dioxo- 494 thiopyran-4-yl)-2(S)-hydroxy-butyl]- amide; 226. Quinoxaline-2-carboxylic acid {1(S)- 640, benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2- 622 (6-methoxy-1H-indol-3-yl)- ethylcarbamoyl]-7-methyl-octyl}-amide, 227. Quinoxaline-2-carboxylic acid 135 587, [1(S)-benzyl-7-fluoro-2(S)-hydroxy- 569 4(R)-(2-methoxy-benzylcarbamoyl)-7- methyl-octyl]-amide 228. Quinoxaline-2-carboxylic acid 587, [1(S)-benzyl-7-fluoro-2(S)-hydroxy- 569 4(R)-(3-methoxy-benzylcarbamoyl)-7- methyl-octyl]-amide 229. Quinoxaline-2-carboxylic acid [1(S)- 152-154 577 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-(2-thiophen-2-yl-ethylcarbamoyl)- octyl]-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 230. Quinoxaline-2-carboxylic acid {1(S)- 107-108 610 benzyl-7-fluoro-2(S)-hydroxy-4(R)-[2- (1H-indol-3-yl)-ethylcarbamoyl]-7- methyl-octyl}-amide 231. Quinoxaline-2-carboxylic acid {4(R)-[2- 586 (4-amino-phenyl)-ethylcarbamoyl]- 1(S)-benzyl-7-fluoro-2(S)-hydroxy-7- methyl-octyl)-amide 232. Quinoxaline-2-carboxylic acid {1(S)- 109-112 631, benzyl-4(R)-[2-(3,5-dimethoxy-phenyl)- 613 ethylcarbamoyl]-7-fluoro-2(S)-hydroxy- 7-methyl-octyl}-amide 233. Quinoxaline-2-carboxylic acid {1(S)- 631, benzyl-4(R)-[2-(3,4-dimethoxy-phenyl)- 613 ethylcarbamoyl]-7-fluoro-2(S)-hydroxy- 7-methyl-octyl}-amide 234. Quinoxaline-2-carboxylic acid {1(S)- 155.5-156.5 547 benzyl-7-fluoro-4(R)-[(furan-2- ylmethyl)-carbamoyl]-2(S)-hydroxy-7- methyl-octyl}-amide 235. Quinoxaline-2-carboxylic acid {1(S)- 631, benzyl-4(R)-[2-(2,5-dimethoxy-phenyl)- 613 ethylcarbamoyl]-7-fluoro-2(S)-hydroxy- 7-methyl-octyl}-amide 236. Quinoxaline-2-carboxylic acid 114-115 587, [1(S)-benzyl-7-fluoro-2(S)-hydroxy- 569 4(R)-(4-methoxy-benzylcarbamoyl)-7- methyl-octyl]-amide 237. Quinoxaline-2-carboxylic acid 150-152 505, 1(S)-benzyl-4(R)-carbamoyl-6- 487 cyclohexyloxy-2(S)-hydroxy-hexyl)- amide 238. Quinoxaline-2-carboxylic acid {4(R)- 596 [(1H-benzoimidazol-2-ylmethyl)- carbamoyl]-1(S)-benzyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl}-amide 239. Quinoxaline-2-carboxylic acid [1(S)- 217-219 551, benzyl-7-fluoro-2(S)-hydroxy-4(R)- 533 (2(S)-hydroxymethyl-pyrrolidine-1- carbonyl)-7-methyl-octyl]-amide 240. Quinoxaline-2-carboxylic acid {1(S)- 111-115 551, benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 533 4(R)-[(tetrahydrofuran-2-ylmethyl)- carbamoyl]-octyl}-amide 241. Quinoxaline-2-carboxylic acid [1(S)- 176-179 497, benzyl-4(S)-carbamoyl-4-(4,4-difluoro- 478 cyclohexyl)-2(S)-hydroxy-butyl]-amide TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 242. Quinoxaline-2-carboxylic acid 99-101 [1(S)-benzyl-4(R)-(2,3-dimethoxy- benzylcarbamoyl)-7-fluoro-2(S)- hydroxy-7-methyl-octyl]-amide 243. Quinoxaline-2-carboxylic acid [1(S)- 187-188 477, benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- 379 (1-hydroxy-cyclohexyl)-butyl]-amide; 244. Quinoxaline-2-carboxylic acid [1(S)- 195-198 491 benzyl-4(S)-carbamoyl-4-(2,6-dimethyl- tetrahydro-pyran-4-yl)-2(S)-hydroxy- butyl]-amide; 245. Quinoxaline-2-carboxylic acid 225-227 485, [4(R)-carbamoyl-7-fluoro-1 (S)-(3- 467 fluoro-benzyl)-2(S)-hydroxy-7-methyl- octyll-amide 246. 7,8-Difluoro-quinoline-3-carboxylic acid >220 502, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 485 2(S)-hydroxy-7-methyl-octyl)-amide 247. N-1(S)-Benzyl4( R)-carbamoy 1-7- >220 484, fluoro-2(S)-hydroxy-7-methyl-octyl)- 466 5 ,6-dichloro-nicotinamide 248. Benzofuran-2-carboxylic acid 1(S)- 190-192 455, benzyl-4(R)-carbamoyl-7-fluoro-2(S)- 438 hydroxy-7-methyl-octyl)-amide 249. Cinnoline-4-carboxylic acid 1(5)- 198-199.5 469, benzyl4(R)-carbamoyl-7-fluoro-2(S)- 451 hydroxy-7-methyl-octyl)-amide 250. Quinoxaline-2-carboxylic acid 185.5-187.5 593, [4(R)-carbamoyl-7-fluoro-2(S)-hydroxy- 576 I (S)-(4-iodo-benzyl)-7-methyl-octyl]- amide, 251. Pyrazine-2-carboxylic acid 211-212 417, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 319 2(S)-hydroxy-7-methyl-octyl)-amide, 252. 6,7,8-Trifluoro-quinoline-3-carboxylic 195-197 520, acid 503 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 2(S)-hydroxy-7-methyl-octyl)-amide, 253. Quinoline-6-carboxylic acid 170-173 466, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 449 2(S)-hydroxy-7-methyl-octyl)-amide, 254. Isoquinoline-3-carboxylic acid 194-197 466, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 448 2(S)-hydroxy-7-methyl-octyl)-amide, 255. 2-Methoxy-quinoline-3carboxylic acid 213-216 496, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 479 2(S)-hydroxy-7-methyl-octyl)-amide, TABLE 1 EXAMPLE NAME M.P. ("C) LRMS 256. 1H-Benzoimidazole-2-carboxylic acid 168-169 456, 1 (S)-benzyl4(R)-carbamoyl-7-fluoro- 438 2(S)-hydroxy-7-methyl-octyl)-amide, 257. Benzothiazole-2-carboxylic acid 152.5-155 472, 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 455 2(S)-hydroxy-7-methyl-octyl)-amide 258. 5-Methyl-pyrazine-2-carboxylic acid 194-197 431 1(S)-benzyl-4(R)-carbamoyl-7-fluoro- 2(S)-hydroxy-7-methyl-octyl)-amide 259. Quinoxaline-2earboxylic acid 470, I (S)-benzyIA(R)rbamoyI-2(S)- 453 hydroxy-5-pyridin-3-yl-pentyl)-amide 260. Quinoxaline-2-carboxylic acid [1(S)- 210-211 477, benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- 459 (1-hydroxy-cyclohexyl)-butyl]-amide; 261. Quinoline-3-carboxylic acid (1(S)- 231 460, benzyl-4(S)-carbamoyl-4-cyclohexyl- 443 2(S)-hydroxy-butyl)-amide 262. Quinoline-2-carboxylic acid (1(S)- 208-210 460, benzyl-4(S)-carbamoyl-4-cyclohexyl- 443 2(S)-hydroxy-butyl)-amide 263. Fluoro-quinoline-3-carboxylic acid 238-240 478, (1(S)-benzyl-4(S)-carbamoyl-4- 461 cyclohexyl-2(S)-hydroxy-butyl)-amide 264. N-(1(S)-Benzyl-4(S)-carbamoyl-4- 174-177 461 cyclohexyl-2(S)-hydroxy-butyl)-5,6- dichloro-nicotinamide; 265. N-( 1 (S)-Benzyl4(S)-carbamoyl4- 255-256 475, cyclohexyl-2(S)-hydroxy-butyl)-5- 458 bromo-nicotinamide; 266. Quinoxaline-2-carboxylic acid 159-160.5 453 (4(R)-carbamoyl-7-fluoro-2(S)-hydroxy- 7-methyl-1(S)-phenyl-octyl)-amide, 267. Quinoxaline-2-carboxylic acid 470, I (S)-benzyl4(R)-carbamoyl-2(S)- 453 hydroxy-5-pyridin-2-yl-pentyl)-amide, 268. Quinoxaline-2-carboxylic acid [4(R)- 206-207 482 carbamoyl-2(S)-hydroxy4-(1 -hydroxy- cyclohexyl)-1 (S)-thiophen-2-ylmethyl- butyl]-amide; 269. Quinoxaline-2-carboxylic acid [1 (S)- 123-125 495, benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- 379 (4-hydroxy-tetrahydro-thiopyran-4-yl)- butyl]-amide; 270. 1,3-Dimethyl-1 H-pyrazolo[3,4- 189.5-191 484, b]pyridine-5-carboxylic acid 1(S)- 467 benzyl-4(R)-carbamoyl-7-fluoro-2(S)- hydroxy-7-methyl-octyl)-amide, TABLE 1 EXAMPLE NAME M.P.(°C) LRMS 271. Quinoxaline-2-carboxylic acid (1(S)- 165-166 benzyl-7-fluoro-2(S)-hydroxy-4(R)- hydroxycarbamoyl-7-methyl-octyl)- amide 272. Quinoxaline-2-carboxylic acid (1(S)- benzyl-7-fluoro-2(S)-hydroxy4(R)- methoxycarbamoyl-7-methyl-octyl)- amide 273. 7,8-Difluoro-quinoline-3carboxylic acid 233-235 (1 (S)-benzyl4(R)-carbamoyl-2(S)- hydroxy-5-phenyl-pentyl)-amide 274. Quinoxaline-2-carboxylic acid 11 (S)- 182-185 benzyl-4(R)-carbamoyl-5-(2-chloro- phenyl)-2(S )-hydroxy-penty I]-amide 275. Quinoxaline-2-carboxylic acid (1(S)- 168-171 benzyl4(R)-carbamoyl-2(S)-hydroxy- 5-o-tolyl-pentyl)-amide 276. Quinoxaline-2-carboxylic acid (1(S)- 190-192 benzyl-2(S)-hydroxy-4(R)- hydroxycarbamoyl-5-phenyl-pentyl)- amide 277. Quinoxaline-2-carboxylic acid [1(S)- 192-195 463, benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- 446 (1 -hydroxy-cyclopentyi)-butyl]-amide 278. Quinoxaline-2-carboxylic acid [1(S)- 230-233 490 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-4-methyl-cyclohexyl)-butyl]- amide 279. Quinoxaline-2-carboxylic acid [I (S)- 199-201 benzyl-4(S)-carbamoyl-5-(3,4-dichloro- phenyl)-2(S)-hydroxy-pentyl]-amide 280. Quinoxaline-2-carboxylic acid [I(S)- 171-173 benzyl4(R)-carbamoyl-5-(2-fluoro- phenyl)-2(S)-hydroxy-pentyl]-amide 281. Quinoxaline-2-carboxylic acid [1(S)- 110-112 477 benzyl-2(S)-hydroxy-4(S)- hydroxycarbamoyl-4-(1-hydroxy- cyclopentyl)-butyl]-amide 282. Quinoxaline-2-carboxylic acid [1(S)- 187-188 476 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-3-methyl-cyclopentyl)- butyl]-amide 283. Quinoxaline-2-carboxylic acid [1(S)- 114-116 506 benzyl-2(S)-hydroxyA(S)- hydroxycarbamoyl4-( l-hydroxy-4- methy -cyclohexy I)-butyl]-amide 284. N-(1(S)-Benzyl-4(R)-carbamoyl-2(S)- 494, hydroxy-5-phenyl-pentyl)-5-bromo- 496 nicotinamide TABLE 1 EXAMPLE NAME M.P. (°C) LRMS 285. 8-Fluoro-quinoline-3-carboxylic acid 206-209 (1 (S)-benzyl4(R)-carbamoyl-2(S)- hydroxy-5-phenyl-pentyl)-amide 286. 6,7-Dihydro-5H-[1 ]pyrindin3- 182-186 carboxylic acid (1(S)-benzyl4(R)- carbamoyl-2(S)-hydroxy-5-phenyl- pentyl)-amide 287. Quinoline-3-carboxylic acid (1(S)- 203-206 benzyl4(R)-carbamoyl-2(S)-hydroxy- 5-phenyl-pentyl)-amide 288. Quinoxaline-2-carboxylic acid [1(S)- 234-236 504 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-3,5-dimethyl-cyclohexyl)- butyl]-amide 289. Quinoxaline-2-carboxylic acid [1(S)- 520 benzyl-2(S)-hydroxy-4(S)- hydroxycarbamoyl-4-(1-hydroxy-3,5- dimethyl-cyclohexyl)-butyl]-amide 290. Quinoxaline-2-carboxylic acid [1(S)- 189-191 491 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1 -hydroxy-cycloheptyl)-butyl]-amide 291. Quinoxaline-2-carboxylic acid [1 (S)- 118-119 506 benzyl-2(S)-hydroxy4(S)- hydroxycarbamoyl4-( l-hydroxy- cycloheptyl)-butyll-amide 292. Quinoxaline-2-carboxylic acid [1 (S)- 176-179 benzyl-4(R)-carbamoyl-5-(3-fluoro- phenyl)-2(S)-hydroxy-pentyl]-amide 293. Quinoxaline-2-carboxylic acid (1(S)- 178-179 benzyl-4(R)-carbamoyl-2(S)-hydroxy- 5-m-tolyl-pentyl)-amide 294. Quinoxaline-2-carboxylic acid (1(S)- 146-148 benzyl-2(S)-hydroxy4- isobutylcarbamoyl-butyl)-amide 295. - Quinoxaline-2-carboxylic acid [1(S)- 206-207 | 528 benzyl4(S)-carbamoyl-2(S)-hydroxy4- (2-hydroxy-adamantan-2-yl)-buty I]- amide 296. Quinoxaline-2carboxylic acid [1(S)- 268-269 516 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (9-hydroxy-bicyclo[3.3.1]non-9-yl)- butyll-amide 297. Quinoxaline-2-carboxylic acid [1(S)- 133-134 544 benzyl-2(S)-hydroxy-4(S)-(2-hydroxy- adamantan-2-yl)-4-hydroxycarbamoyl- butyl]-amide 298. Quinoxaline-2-carboxylic acid [1 (S)- 130-132 532 benzyl-2(S)-hydroxy4(S)-(9-hydroxy- bicyclo[3.3.1]non-9-yl)-4- hydroxycarbamoyl-buty l]-amide TABLE 1 EXAMPLE NAME M.P. (°C) LRMS 299. Quinoxaline-2-carboxylic acid [1(S)- 147-148 benzyl-4(R)-carbamoyl-2(S)-hydroxy- 5-(3-methoxy-phenyl)-pentyl]-amide 300. Quinoxaline-2-carboxylic acid [1(S)- 227-228 519 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-4-propyl-cyclohexyl)-butyl]- amide 301. Quinoxaline-2-carboxylic acid [1 (S)- 115-117 533 benzyl-2(S)-hydroxy4(S)- hydroxycarbamoyl4-( l-hydroxyS- propyl-cyclohexyl)-butyl]- amide 302. Quinoxaline-2-carboxylic acid [1(S)- 500, benzyl-4(R)-carbamoyl-2(S)-hydroxy- 483 5-(4-methoxy-phenyl)-pentyl]-amide 303. Quinoxaline-2carboxylic acid [1 (S)- 246-248 504 benzyl-4(S)-carbamoyl-4(S)-(4-ethyl-1- hydroxy-cyclohexyl)-2-hydroxy-butyl]- amide 304. Quinoxaline-2-carboxylic acid [1 (S)- 210-211 505 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-4,4-dimethyl-cyclohexyl)- butyli-amide 305. Quinoxaline-2-carboxylic acid [1(S)- 118-123 benzyl-2(S)-hydroxy-4(S)- hydroxycarbamoyl-4-(1-hydroxy-4,4- dimethyl-cyclohexyl)-but yl]-amide 306. Quinoxaline-2-carboxylic acid [1(S)- 207.5-208.5 benzyl-4(S)-carbamoyl-4-(4,4-difluoro- 1-hydroxy-cyclohexyl)-2(S)-hydroxy- butyl]-amide 307. Quinoxaline-2carboxylic acid [1 (S)- 130-131 572 benzyl4(S)-(4,4-difluoro-1 -hydroxy- cyclohexyl)-2(S)-hydroxy-4- hydroxycarbamoyl-but yl]-amide 308. Quinoxaline-2-carboxylic acid [1(S)- 250-252 545 benzyl-4(S)-carbamoyl-2(S)-hydroxy-4- (1-hydroxy-4-trifluoromethyl- cyclohexyl)-butyl]-amide 309. Quinoxaline-3- carboxylic acid 1(S)- 94-98 454 cyclohexylmethyl-2(S)-hydroxy-6- methyl-4(R)-methylcarbamoyl-heptyl)- amide 310. Quinoxaline-2-carboxylic acid [1 (S)- 174-175.5 522 benzyl-7-fluoro-2(S)-hydroxy-7-methyl- 4(R)-(pyrrolidine-1-carbonyl)-octyl]- amide 311. N-(1(S)-Benzyl-4(S)-carbamoyl-4- 218-220 470 cyclohexyl-2(S)-hydroxy-butyl)-5- bromo-nicotinamide

TABLE 1 EXAMPLE NAME M.P. (°C) LRMS 312. Quinoxaline-2-carboxylic acid (1(S)- 147-149 482,467 benzyl-7-fluoro4(R)- hydrazinocarbonyl-2(S)-hydroxyl-7- methyl-octyl)-amide EXAMPLE 313 Quinoxaline-2-carboxylic acid 1(S)-benzyl-4(R)-carbamoyl-2(S), 7-dihydroxy-7- methyloctyl)-amide To the lactone from Example 2, method C (100 mg, 0.27 mmol), was added neat trifluoroacetic acid (1 mL). The resulting solution was stirred for 1 hour and the trifluoroacetic acid removed in vacuo. The remaining residue was solvated in methylene chloride (10 mL) and triethylamine (0.15 mL, 1.07 mmol). Quinoxalyl chloride (58 mg, 0.3 mmol) was added as a solid and the mixture stirred for 18 hour. The mixture was transferred to a separatory funnel and washed with citric acid (2x10 mL), NaHOO3 (10 mL) and brine (10 mL). The organic layer was dried (MgS04) and the solvents filtered. The filtrate was concentrated in vacuo and the resulting residue was chromatographed on silica gel (10 g) eluting with 2:1 hexanes:ethyl acetate to provide 99 mg of the quinoxaline amide. This material was solvated in methanol and ammonia gas was bubbled in for 5 minutes. The resulting solution was stirred for 16 hours and the solvent removed in vacuo. The remaining residue was recrystallized (methylene chloride/methanol/Hexanes) to provide the title compound (90 mg, 72%). 1H NMR (400 MHz, CD30D): d 9.38 (1H, s), 8.21 (1H, dd, J=4.4, 2.5 Hz), 8.14 (1H, dd, J=4.4, 2.5 Hz), 7.93 (2H, m), 7.26 (2H, d, J=6.9 Hz), 7.17 (2H, t, J=7.1 Hz), 7.09 (1H, t, J=7.3 Hz), 4.30 (1H, m), 3.75 (1H, m), 3.03-2.98 (2H, m), 2.47 (1H, m), 1.77 (1H, m), 1.56 (2H, m), 1.4 (2H, m), 1.07 (6H, s).

EXAMPLES 314-344 The compounds from Table 2 were prepared according to the methods described above, substituting where appropriate the correct R2 aldehyde, R3 group, R' carboxylic acid or R4 and R5 amine where appropriate.

TABLE 2 EXAMPLE NUMBER | NAME MP LRMS 314 | Quinoxaline-2-carboxylic acid 153-155 483., 465.. 448 [4(R)-carbamoyl-I 1(S)-(3- fluoro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]- amide EXAMPLE NUMBER NAME MP LRMS 315 Quinoxaiine-2-carboxylic acid 162-163 500, 483, 466 [4(R)-carbamoyl-1(S)-(3,5- difluoro-benzyl)- 2(S),7-dihydroxy-7-methyl- octyl]-amide 316 Quinoxaline-2-carboxylic acid 161-163 499, 481, 464 4(R)-carbamoyl-1(S)-(3- chloro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]- amide 317 Quinoxaline-2-carboxylic acid 108-111 497, 464 [1(S)-(3-chloro-benzyl)- 2(S),7-dihydroxy-4(R)- hydroxycarbamoyl-7-methyl- octyll-amide 318 7,8-Difluoro-quinoline-3- 171-173 501, 484 carboxylic acid (1S)-benzyl- 4(R)-carbamoyl-2(S),7- dihydroxy-7-methyl-octyl)- amide 319 6,7,8-Trifluoro-quinoline-3- 185-188 519, 502 carboxylic acid (1(S)-benzyl- 4(R)-carbamoyl- 2(S),7-dihydroxy-7-methyl- octyl)-amide 320 Quinoxaline-2-carboxylic acid 98-100 517 [1 (S)-(3,5-difluoro-benzyl)- 2(S),7-dihydroxy- 4(R)-hydroxycarbamoyl-7- methyl-octyl]-amide 321 Quinoxaline-2-carboxylic acid 108-110 482, 464, 447 (1 (S)-benzyl-2(S),7- dihydroxy4(R)- hydroxycarbamoyl-7-methyl- octyl)-amide 322 7,8-Difluoro-quinolEne-3- 507, 484, 447 carboxylic acid (1(S)-benzyl- 4(R)-ethylcarbamoyl- 2(S),7-dihydroxy-7-methyl- octyl)-amide 323 N-(1(S)-Benzyl4(R)- 131-135 482, 464, 447 carbamoyl-2(S),7-dihydroxy- 7-methyl-octyl)-4- trifluoromethyl-nicotinamide 324 Quinoxaline-2-carboxylic acid [4(R)-carbamoyl-1 (S)-(2- chloro-benzyl)-2(S),7- EXAMPLE NUMBER NAME MP LRMS dihydroxy-7-methyl-octyl]- amide 325 7,8-Difluoro-quinoline-3- 174-177 518 carboxylic acid [(4R)- carbamoyl-1(S)-(3-fluoro- benzyl)-2(S),7-dihydroxy-7- methyl-octyl]-amide 326 Quinoxaline-2-carboxylic acid 130-131 499 [1(S)-(2-fluoro-benzyl)- 2(S),7-dihydroxy-4(R)- hydroxycarbamoyl-7-methyl- octyll-amide 327 Quinoxaline-2-carboxylic acid 158-159 471, 453, 436 (4(R)-carbamoyl-2(S),7- dihydroxy-7-methyl-1(S)- thiophen-2-ylmethyl-octyl)- amide 328 Quinoxaline-2-carboxylic acid 147-148 483 [4(R)-carbamoyl-1 (S)-(2- fluoro-benzyl)-2(S),7- dihydroxy-7-methyl-octyl]- amide 329 Quinoxaline-2-carboxylic acid 150-153 517, 499, 466 [1 (S)-(3,4-difluoro-benzyl)- 2(S),7-dihydroxy- 4(R)-hydroxywarbamoyl-7- methyl-octyl]-amide 330 Quinoxaline-2-carboxylic acid 110-120 501, 483, 466 [4(R)-carbamoyl-1(S)-(3,4- difluoro-benzyl)- 2(S),7-dihydroxy-7-methyl- octyl]-amide 331 Quinoxaline-2-carboxylic acid 155-158 515, 497, 480 (4(R)-carbamoyl-2(S),7- dihydroxy-7-methyl-1(S)- naphthalen-1 -ylmethyl-octyl)- amide 332 6,7,8-Trifluoro-quinoline-3- 183-185 536, 518 carboxylic acid [4(R)- carbamoyl-l (S)-(3-fluoro- benzyl)-2(S),7-dihydroxy-7- methyl-octyll-amide 333 Quinoxaline-2-carboxylic acid 104-106 515, 497 (4(R)-carbamoyl-2(S),7- dihydroxy-7-methyS1 (S)- naphthalen-2-ylmethyl-octyl)- amide EXAMPLE NUMBER NAME MP LRMS 334 Quinoxaline-2-carboxylic acid 98-100 498, 480 (2(S),7-dihydroxy-4(R)- hydroxycarbamoyl-7- methyl-1(S)-naphthalen-2- ylmethyl-octyl)-amide 335 Quinoxaline-2-carboxylic acid 163-164 521, 503, 486 (1(S)-benzo[b]thiophen-3- ylmethyl-4(R)- carbamoyl-2(S),7-dihydroxy- 7-methyl-octyl)-amide 336 Quinoxaline-2-carboxylic acid 190.5-191.5 [1-benzyl-4-carbamoyl-2- hydroxy-5-(4- hydroxy-phenyl)-pentyl]- amide 337 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(3- hydroxy-phenyl)-pentyl]- amide 338 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(2- hydroxy-phenyl)-pentyl]- amide 339 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(2- hydroxy-5-methyl-phenyl)- pentyl]-amide 340 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(2- hydroxy-3-methyl-phenyl)- pentyl]-amide 341 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-5-(3- ethoxy-2- hydroxy-phenyl)-2-hydroxy- pentyl]-amide 342 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(4- hydroxy-3,5-dimethyl- phenyl)-pentyl]-amide 343 Quinoxaline-2-carboxylic acid (1-benzyl-4-carbamoyl-2,6- dihydroxy-6- methyl-heptyl)-amide EXAMPLE NUMBER NAME MP LRMS 344 Quinoxaline-2-carboxylic acid [1-benzyl-4-carbamoyl-2- hydroxy-5-(1- hydroxy-cyclohexyl)-pentyl]- amide